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ABSTRACT
Insulin detemir is an intermediate acting basal insulin bound to albumin via its 14C fatty 
acid side chain. Insulin detemir may have a more physiological action because it is believed 
that compared to NPH insulin (Neutral Protamine Hagedom) it is preferentially cleared by 
the liver. This increased clearance may occur due to the open sinusoids of the endothelial 
membrane in the liver allowing the passage of larger molecules, such as the albumin bound 
insulin detemir, when compared to the tight endothelial junction in the periphery. This 
theory may explain why there is less hypoglycaemia and less weight gain observed in 
clinical trials when used as part of a basal bolus regime in comparison to NPH insulin.
The glucose lowering effect of insulin detemir compared to NPH insulin administered 
subcutaneously to subjects with type 1 diabetes was investigated in a randomised, double 
blind, cross over study. The first five individuals received 0.4 Units/kg. The insulin dose 
was increased for the subsequent 18 subjects to 0.5 Units/Kg to achieve more consistent 
hypoglycaemia. The glucose lowering effect o f each insulin was compared along with 
symptoms of hypoglycaemia, effects on cognitive and autonomic function and 
counterregulatory responses (adrenaline, noradrenaline, glucagon, cortisol, growth hormone, 
IGFBP1 and NEFA). The effect on endogenous glucose production and peripheral glucose 
uptake were also compared using stable isotope techniques.
The data analysis was performed on 14 subjects who achieved adequate hypoglycaemia 
when dosed at 0.5 units/Kg. The glucose lowering effect of both NPH and insulin detemir 
were equivalent, no significant differences were observed in symptoms of hypoglycaemia,
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effects on cognitive or autonomic function or counterregulatory hormone responses. At or 
below a glucose concentration of 3.5 mmol/1 suppression of endogenous glucose production 
was shown to be greater with insulin detemir than NPH insulin (p=0.001) and stimulation of 
peripheral glucose uptake was shown to be greater with NPH insulin when compared to 
insulin detemir (p=0.005). This would suggest that insulin detemir had a greater effect on 
the liver than in the periphery when compared to NPH insulin.
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Chapter 1
INTRODUCTION  
Diabetes 
Definition o f Diabetes
Diabetes mellitus is a group of metabolic diseases which are associated with symptoms of 
excessive thirst, increased urine volume and weight loss caused by the osmotic effect of 
chronic hyperglycaemia. It results from the insufficiency of or diminished effectiveness of 
endogenous insulin. The glycaemic threshold for diagnosis was originally derived from 
epidemiological studies where risk for developing the microvascular complication of 
retinopathy was plotted against plasma glucose (National Diabetes Data Group 1979). Over 
the years this threshold has been revised as more evidence of the long term effects and 
complications related to hyperglycaemia have been established. These long term effects 
include damage to the eyes, kidneys, nerves, heart and blood vessels. The strongest 
association of plasma glucose remains retinopathy, a threshold for proteinuria or 
cardiovascular disease has not been as clear. The current criteria distinguish a group with 
significantly increased premature mortality and increased risk of microvascular and 
cardiovascular complications.
In the short term apart from polyuria, polydipsia and weight loss, type 1 diabetes can be life 
threatening due to the development of hyperglycaemia with ketoacidosis. This is due to 
absolute lack of insulin which is treated by insulin replacement therapy. The vast majority of 
diabetes falls into two distinct epidemiological categories as outlined below: type 1 and type 
2 diabetes. This review and study focuses on type 1 diabetes. Immune mediated type 1 
diabetes (|3 cell destruction leading to absolute insulin deficiency) accounts for 5-10% of 
those with diabetes (position statement ADA 2004)
14
Diagnosis of Diabetes
The World Health Organisation (WHO) / International Diabetes Federation (IDF) 
(November 2005) set out the following criteria for the diagnosis of diabetes mellitus:
1. Symptoms of diabetes plus plasma glucose concentration >200mg/dl (11.1 mmol/1) at any 
time of day without regard to the time since last meal. The classic symptoms of diabetes 
include polyuria, polydipsia and unexplained weight loss.
Or
2. Fasting plasma glucose > 126mg/dl (7.0mmol/l). Fasting is defined as no calorie intake 
for at least 8 hours.
Or
2-hour plasma glucose >200mg/dl (11.1 mmol/1) during an OGTT. The test should be 
performed as described by WHO, using a glucose load containing the equivalent of 75mg 
anhydrous glucose dissolved in water.
In the absence of unequivocal hyperglycaemia with acute metabolic decompensation, these 
criteria should be confirmed by repeat testing on a different day.
15
Table 1: Classification of diabetes (American Diabetes Association 2007)
Diabetes Mellitus
Type 1 Diabetes Type 2 
diabetes
Other types of diabetes Gestational
Diabetes
A. Autoimmune
B. Idiopathic
A. Genetic defects of the beta cell
B. genetic defects of insulin action
C. diseases of the pancreas
D. Endocrinopathies
E. Drug or chemical induced
F. Infections
G. Uncommon forms of immune 
mediated diabetes
H. Other genetic syndromes 
sometimes associated with 
diabetes
History o f Diabetes.
In 1552 BC, the earliest mention of diabetes was recorded by the Egyptian physician Hesy- 
Ra on papyrus mentioning polyuria as a symptom. Early Hindu writings attributed to Susrata 
in 400BC, describe people with a mysterious and deadly disease that caused increased thirst, 
enormous urine output and wasting away of the body whose urine was attractive to black 
ants. (MacCracken 1997). Areteus of Cappadocia a contempory of Nero (30-90 AD) wrote 
“diabetes is a strange disease, which fortunately is not very frequent. It consists o f  the flesh  
and bones running together into the urine....The illness develops very slowly. Its final 
outcome is death... The patients are tortured by an unquenchable thirst; they never cease 
drinking and urinating.... The disease was called diabetes, as though it were a siphon 
because it converts the human body into a pipe fo r the transflux o f  liquid humors. Now 
since the patient goes on drinking and urinating while only the smallest portion o f  what he
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drinks is assimilated in the body, life naturally cannot be preserved fo r  very long, fo r  a 
portion o f  the flesh is also excreted through the urine. ” (Hoskins, 1941). The term diabetes 
(from Greek Dia, through and baino meaning “siphon”) had actually been coined earlier by 
Apollonius of Memphis and Demetrius of Apamea around 250 BC.
Up to the 11th century diabetes was commonly diagnosed by “water tasters” who drank the 
urine of people thought to have diabetes, it tasted sweet and hence the word “mellitus” was 
added as a result. In 1674 Thomas Willis re-described the presence of glycosuria (the 
“pissing evile” urine “wonderfully sweet”) and concluded that this must be preceded by 
presence of sweetness in the blood. In the same year Brunner carried out the first 
pancreatectomy in dogs reproducing the symptoms of diabetes. In 1774 Matthew Dobson 
demonstrated that the sweetness of urine and serum was due to sugar. In 1849 Claude 
Bernard working on carbohydrate metabolism in the liver linked diabetes with glycogen 
metabolism. In 1869 Paul Langerhans, a German medical student in Berlin, described small 
bodies in the pancreas, one set of cells secreting pancreatic juice and the other’s function 
unknown. Unfortunately he was unable to continue his work, he developed tuberculosis and 
had to leave Germany to live in Madeira, where he died at the age of 40 (Andreani, 1999). In 
the 1870’s French physician Bouchardet noticed the disappearance of glycosuria in his 
diabetes patients during the Franco-Prussian War food rationing and formulated an 
individualised diet for his patients.
Frederick Pavey (1829-1911) studied a large number of patients with diabetes prompting 
Queen Victoria’s physician Sir William Gull to observe “What sin has Pavey committed or 
his fathers before him, that he should be condemned to spend the rest of his life seeking a 
cure for an incurable disease?”
In the late 19th Century Minkowski and von Mehring were interested in the study of the 
pancreas in relation to digestion, however it was a kennel worker who was caring for the 
experimental animals of the two doctors who noticed that their urine was attracting great 
swarms of flies. He drew the doctor’s attention to this and it was discovered the urine had 
large amounts of sugar (Minkowski later denied this version of events). Minkowski
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recognised the significance of the discovery and tried to make an extract of dog’s pancreas 
that would have a beneficial effect on the experimental diabetes he had produced but 
without success. Another physician, Caparelli discovered a simple saline extract of pancreas 
injected directly into the abdominal cavity of dogs had a marked lessening or even 
disappearance of glucose in the urine.
Clinicians immediately attempted to use the knowledge, some administered fresh pancreas 
by mouth, some gave juice expressed from the gland, and some administered extracts 
rectally. Bormann administered roast pancreas by mouth, later infusions by rectum and 
finally subcutaneous injections of raw pancreas extract. One of his patients who received 
the latter treatment gained eight pounds in six weeks. Others were finding similar results 
however these pancreatic extract contained digestive enzymes and patients were unable to 
tolerate the injections for long (Hoskins 1941). In 1898 Blumenthal squeezed the juice from 
raw pancreas and treated it with alcohol to remove the protein. When administered 
intravenously it killed his experimental animals, and when injected subcutaneously caused 
ulcers however he was able to show that subcutaneous injection of his preparation increased 
glucose utilization by 40%. Blumenthal was actually using a crude preparation of insulin, 
and had his side effects been less severe he may have been credited with the discovery of 
insulin therapy.
Frederick Madison Allen (bom in 1876) working at Harvard Medical school, carried out 
extensive work on diabetes and carbohydrate metabolism and founded the “Allen’s diets”. 
He concluded that while diabetes was mostly a problem of carbohydrate metabolism, it was 
not just the carbohydrates but the proteins and fats as well. Diets that involved cutting back 
sharply on carbohydrates and increasing proteins and fats achieved little and if anything 
caused a deterioration in the condition with a higher rate of acidosis and death resulting from 
the metabolism of fats. Described as a stem, cold, tireless scientist (Bliss 1983) Allen had a 
ward of patients with diabetes at the Rockefeller Institute in New York. Here he applied his 
diets to an assortment of patients with diabetes restricting some to as little as 400 calories 
per day. He published his findings of 76 of the 100 patients he treated in 1919 (total dietary 
regulation in the treatment of diabetes); some patients survived for a few years others only
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for a few months. Allen’s diets were generally thought to be the best therapy at the time and 
were adopted by medical schools and up to date practitioners.
In 1908 Georg Ludwig Zuelzer a young German physician collected pancreas glands from 
animals at the height of digestion. He pressed out the juice and treated it with alcohol to 
precipitate the proteins. The material was then freed from the alcohol and injected into 
dogs. He managed to reduce the urine sugar output in these dogs with the substance he 
called “acomatrol”. He treated 8 patients and successfully reduced the amount of sugar in 
their urine. He went on to inject acomatrol into a fifty year old with diabetes in a private 
clinic in Berlin. The patient was comatose, but after receiving the extract his condition 
improved, only to deteriorate and die when supplies of Zuelzer’s acomatrol dried up 
(MacCracken 1997). His extract needed purifying further to decrease the side effects of 
vomiting, high fevers and convulsions that his patients were suffering. Zuelzer continued to 
attempt to make a pancreas preparation suitable for the treatment of diabetes. He visited 
many pharmaceutical companies to try to gain backing without success. Finally in 1911 he 
was given funding by one, however he had little success and in 1914 his hospital was taken 
over by the military. The presence of digestive enzymes in the pancreatic products was 
causing great difficulties.
In 1921 Banting, at the time an orthopaedic surgeon, returned from the war. On reading an 
article by Barron written in 1920 describing the old experiment of ligating the pancreatic 
ducts which results in atrophy of the exocrine pancreas leaving the islets intact, it occurred 
to him that the troublesome digestive enzymes may be circumvented using this technique. 
Under Professor Macleod at the University of Toronto he was given the assistance of Best, a 
medical student. They started ligating ducts in the pancreas of dogs and after the pancreas 
had degenerated injected extracts of it into depancreatised dogs. They recorded a lowering 
of the urine sugar output, however they soon ran out of pancreatic tissue. At this point they 
too were confronted with the problem of preparation and refinement of the extracts of 
pancreatic tissue. Collip was then added to the group and brought the experience gained in 
several years of devotion to this type of chemistry. They moved on to using the fetal calf 
pancreas to avoid the activity of trypsin, and then onto ox pancreas, with which they
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discovered that if the whole gland was immediately placed in acid aqueous alcohol it yielded 
adequate amounts of insulin. The use of alcohol and acid in the extraction process 
circumvented the enzyme action. The resulting extract in concentrated form was first given 
to the investigators themselves.
In January 1922 its first use in patients was begun. Leonard Thompson a 14 year old 
weighing only 641b was the first patient to be given insulin. He received 7.5 ml in each 
buttock of “thick brown muck”. Although initially his blood sugar and glycosuria fell, 
unfortunately he developed abscesses at the injection sites and became more unwell. The 
injections were stopped. Six weeks later he was given Collip’s more refined extract, his 
blood sugar fell and he quickly began to gain weight. Collip’s extract was then given to a 
number of patients with diabetes at Toronto General Hospital, they responded well. During 
the summer of 1922 insulin began being produced commercially by Eli Lilly in Indianapolis, 
USA. The first insulin complementary deoxyribonucleic acid (cDNA) was cloned and 
sequenced from rat islet messenger ribonucleic acid (mRNA) by Ullrich et al (1977). The 
human insulin gene was later fully characterised (Bell et al 1980, Owerbach et al 1981) and 
the human insulin gene was located to the short arm of chromosome 11. Later recombinant 
DNA techniques allowed biosynthetic human insulin to be produced by Escherichia coli 
(Keefer et al 1981).
Epidemiology
There is much interest and concern about the rising prevalence of diabetes worldwide and 
the resultant chronic disease burden and economic consequences. Most of this increasing 
prevalence reflects the global obesity “epidemic” and the spectrum of impaired glucose 
tolerance and type 2 diabetes but there is also an increase in the prevalence of type 1 
diabetes. In 2010 the estimated diabetes prevalence is 285 million and It is estimated that 
there will be 438 million people worldwide with diabetes by the year 2030 (International 
Diabetes federation atlas 2009) and more than 97% of these will have type 2 diabetes.
Worldwide the incidence of type 1 diabetes ranges from 1.9 to 7.0/100,000/yr in Africa, 0.1 
to 2.5/100,000/yr in South East Asia, 0.1-2.5/100,000/yr in East Asia, 4.4 to 22/100,000/yr
in Australasia, 1.2 to 57.4/100,000/yr in Europe, 1.2 to 22.3/100,000/yr in the Middle East, 
7.61 to 23.7/100,000/yr in North America, and 0.1 to 16.8/100,000/yr in South America (IDF 
atlas 2009). The largest intracontinental variation in incidence appears in Europe, varying 
from the highest in Finland, 57.4 per 100,000, to the lowest in northern Greece at 4.6 per 
100,000 and with “hot spots” such as Sardinia where the incidence approaches that of 
Finland. The incidence is much higher in the Northern hemisphere than the southern.
Prospective national and large international registries (DIAMOND and EURODIAB) have 
demonstrated an increasing trend in incidence in most regions of the world over the last few 
decades and increases seem to be the highest in the youngest age group (Soltesz et al 2007). 
Increases have been reported individually in many European countries and in the UK, in 
Scotland, of about 2 % per annum during the period 1984-1993 (Rangasami et al 1997).
Type 1 diabetes incidence varies by age and sex, with in the UK the peak incidence in boys 
being at 12-13 years and the peak incidence in girls being 9-12 years. The incidence is 
slightly higher in boys than girls (Ratio 1.08: 1) (Wareham et al 2002). This is similar to 
most European countries where it is roughly equal between the sexes. There is also seasonal 
variation in incidence, being highest in autumn and winter.
Pathogenesis o f Type 1 Diabetes
In type 1 diabetes there is a selective destruction of insulin producing cells in the pancreas 
termed “insulinitis”. There are two types; immune mediated and idiopathic (Table 1). The 
first is a cell mediated autoimmune destruction of the p cells of the pancreas which is 
associated with islet cell antibodies, autoantibodies to insulin, antibodies to glutamic acid 
decarboxylase (anti GAD antibodies) and autoantibodies to the tyrosine phosphatases LA-2 
and IA2-P (Roep 1996). There is also an association of diabetes with a restricted set of class 
II major histocompatibility complex (MHC) alleles (Faideau et al 2005).
The second idiopathic group have severe beta cell dysfunction and therefore are ketosis 
prone, can have episodic ketosis and can have a variable clinical course, but no evidence of 
autoimmunity. A minority of people with diabetes fall into this group with mostly African or
Asian ancestry, strong hereditability, not HLA associated and without an immunological 
process. Multiple forms of Beta cell dysfunction seem to underlie the pathophysiology and 
insulin requirement may be intermittent.
Children who develop type 1 diabetes in early childhood (<10 years) can demonstrate islet 
autoimmunity by 2 years of age (Ziegler et al 1999). There is an association of autoimmune 
type 1 diabetes with other autoimmune conditions, the most common being thyroid disease 
(Devendra et al 2003). Approximately 1 in 10 patients with type 1 diabetes express 
transglutaminase IgA autoantibodies and more than half of these patients have coeliac 
disease on intestinal biopsy. Approximately 1 in 50 people with type 1 diabetes have 21- 
hydroxylase autoantibodies, and approximately 25% of these patients progress to Addison's 
disease. Studies measuring the expression of autoantibodies measured from birth in young 
children suggest these are markers of risk for developing type 1 diabetes in the future (Yu et 
al 2000). Pancreatic biopsy from patients with recent onset type 1 diabetes shows an 
insulinitis with an infiltrate of CD4 and CD8 lymphocytes, B lymphocytes and macrophages 
(Imagawaetal 1999).
Interaction of genetic and environmental factors is thought to trigger immune mediated 
diabetes. Less than 10% of genetically susceptible individuals will actually develop type 1 
diabetes (Knip et al 2005). The concordance for type 1 diabetes is approximately 50% for 
monozygotic twins and the risk to a first degree relative is around 5% (Redondo and 
Eisenbarth 1999). Islet auto immunity and type 1 diabetes develop in genetically susceptible 
individuals and a major risk factor is a first degree relative with type 1 diabetes. 
Approximately 10-13% of newly diagnosed children have a first degree relative affected by 
type 1 diabetes (Redondo et al 2002) and this increases with the number of family members 
affected (Bonifacio et al 2004).
There is a well recognised seasonality to type 1 diabetes with incidence being at its highest 
in spring and autumn. This may suggest that certain viruses and maybe diet play a role; this 
theory has been extensively studied. Viruses may cause islet autoimmunity by molecular 
mimicry between amino acid sequences of viral peptides and islet antigens that can activate
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T cells (Wucherpfennig 2001). Viruses that have most commonly been implicated include 
rubella, cytomegalovirus, mumps and Coxsackie’s virus B4. Only congenital rubella 
syndrome has been conclusively associated (Menser et al 1978).
The HLA class II region on chromosome 6 contains the major susceptibility genes thought 
to contribute 50% of the genetic risk for type 1 diabetes (Redondo et al 2002). The major 
histocompatibility complex IDDM1 is a determinant of susceptibility to developing the 
disease with more than 90% of patients having either DR3, DQ2 or DR4, DQ8 haplotypes 
compared to 40% of controls (Atkinson and Eisenbarth 2001). Studies from different 
European countries have confirmed that the HLA DR3-DQ2/DR4-DQ8 genotype is 
associated with the highest diabetes risk. This genotype is found in 20—30% of individuals 
with type 1 diabetes and in almost 50% of those diagnosed in early childhood (Achenbach et 
al 2005). Some genotypes provide protection e.g. the HLA DQ6 genotype (Kumala et al 
2000).
Insulin 
The Insulin Molecule
The insulin molecule was the first protein to have its amino acids sequenced by Fred Sanger 
in 1955, earning him the Nobel Prize in 1958 (Sanger 1988). Insulin has a molecular weight 
of 5808 Daltons containing 55 amino acids arranged in two chains, an A chain of 21 
residues and a B chain of 30 residues, which by themselves are inactive (Figure 1). Working 
with colleagues Sanger later discovered the three disulphide bonds in the unoxidised 
molecule (Ryle et al 1955).
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Figure 1: The structures o f insulin A and B chains.
The figure illustrates insulin A-chain (a) and B-chain (b) as determined from the 3- 
dimensional X-ray analysis of the 2-Zn insulin hexamer. Both chains are viewed 
perpendicular to the 3-fold symmetry axis of the insulin hexamer (www.endotext.com")
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Figure 2: Image of the insulin hexamer showing the Zn at the centre.
Subsequent to the earlier description o f insulin crystallisation (Abel 1926, 1927) it was 
demonstrated that zinc ions (Scott 1934) or certain other metal ions (Schlictkrull 1956) had 
to be added to secure crystallisation. Early X ray crystallography had identified the 
rhombohedral structure o f insulin (Crowfoot 1935) and later work (continued by Hodgkin 
nee Crowfoot) demonstrated that the hexamer o f insulin with a molecular weight o f 36000 
Da, at neutral pH in the presence of zinc, consisted of three slightly asymmetric dimers each 
with a molecular weight of 12000Da (Adams et al 1969, Blundell et al 1971&1972, 
Hodgkin 1972) (Figure 2). Three a helical regions are included in the secondary structure o f 
the molecule, of which two exist on the A chain and one on the B chain (Blundell et al 1971 
& 1972). The folding o f the B chain around the A chain core is also brought about with 
disulphide bridges between cysteine residues. Insulin has a hydrophobic core with polar
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residues on the surface. The non polar residues, mainly on the B chain, are buried during the 
formation of the dimers and the 2-zinc-insulin hexamers (figures 1 and 2). Insulin 
aggregation in solution depends on concentration, pH, ionic strength and the presence of 
divalent cations and anions (Blundell et al 1972, Bradbury and Brown 1977).
Biosynthesis o f Insulin
The P cells in the islets of Langerhans in the pancreas manufacture insulin’s precursor forms 
of prepro insulin and pro insulin in the rough endoplasmic reticulum (Steiner 1967, 1974, 
Patzelt et al 1978). Pro insulin is a single polypeptide chain composed of the A and B 
subunits joined by the C peptide region. It is packed in clathrin coated secretory vesicles in 
the Golgi apparatus of the beta cell along with proinsulin conversion enzymes. As the 
granules mature there is progressive acidification of the vesicular milieu by the influx of H+ 
ions via the proton pump (Molinete et al 2000). This in turn increases the activity of the 
proteolytic enzymes (Orci et al 1987). Proinsulin is cleaved by convertases to form insulin, 
C peptide and two pairs of basic amino acids.
Insulin and C peptide are released at equimolar concentrations along with small amounts of 
proinsulin and its conversion intermediates (Horwitz et al 1975). The most important 
substance involved in the regulation of insulin release is glucose (Porte and Pupo 1969, 
Chen and Porte 1976). Proinsulin can be detected in the circulation however its biological 
potency is only about 10% that of insulin (Melani et al 1970, Bergenstal et al 1984). C 
peptide has no known effects on carbohydrate metabolism.
Insulin is released in a rapid and pulsatile fashion with secretory bursts occurring every 4-15 
min superimposed on basal release (Porksen et al 2002). Insulin is secreted into the portal 
vein circulation and undergoes partial hepatic extraction before dilution into the systemic 
pool (Eaton et al 1983, 1984 Jaspan and Polonsky 1982). In the fasting state during glucose 
infusion both amount of insulin secretion and frequency is increased (Juhl et al 2002).
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Insulin has a short half life of 4-6 minutes as would be expected due to the need to respond 
appropriately to fluctuating glucose concentrations (Duckworth 1988, Morishima et al 
1992). Its effects are mediated by binding to the insulin receptor present in all insulin 
sensitive tissues.
The Insulin Receptor and Insulin Signalling
The insulin receptor belongs to a subfamily of receptor tyrosine kinases which include the 
insulin like growth factor type 1 receptor (IGF1). It sits on the cell surface and is a 
glycoprotein consisting of 2 extracellular a subunits of 135 kDA that bind insulin and 2 
transmembrane p subunits of 95 kDa (Figure 3). The a subunit inhibits the tyrosine kinase 
activity of the (3 subunit (Ebina et al 1985, Ullrich et al 1985). The P subunits are held 
together by disulphide bonds and consist of three regions; an extracellular domain, a 
hydrophobic transmembrane domain and an intra cellular domain, the latter containing 
several sites of autophosphorylation (Kasuga et al 1982 a and b, White et al 1984).
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Figure 3: Activation of the Insulin Receptor. The insulin receptor consists o f 2 
extracellular a  subunits that bind insulin and 2 transmembrane (3 subunits with tyrosine 
kinase activity. Insulin binding to the a subunit induces the transphosphorylation o f one (3 
subunit by another on specific tyrosine residues in an activation loop, resulting in the 
increased catalytic activity of the kinase. The receptor also undergoes autophosphorylation 
at other tyrosine residues in the juxtamembrane regions and intracellular tail. The activated 
IR then phosphorylates tyrosine residues on intracellular substrates. (Chang et al 2004)
Once the insulin receptor has undergone autophosphorylation it catalyses the 
phosphorylation of cellular proteins, after tyrosine phosphorylation these proteins interact 
with signalling molecules (insulin receptor substrate family (1RS)) through their SRc 
homology 2 (SH2) domains resulting in activation o f further signalling pathways (PI (3) K 
(phosphoinositide (3) kinase), MAP kinase (mitogen activated protein cascade) (Saltiel and 
Khan 2001). These pathways then act together to coordinate a number of functions: glucose 
regulation is achieved by glycogen synthesis (i.e. glucose storage) and inhibition of 
gluconeogenesis and glycogenolysis as well as promoting glucose uptake. Protein synthesis 
is stimulated by amino acid uptake into cells and inhibition o f protein degradation. Lipid
synthesis is promoted by the uptake ofNEFA and inhibition of lipolysis. It also has a role in 
gene expression and mitogenic responses (Saltiel and Khan 2001).
The activated receptor exerts a direct effect on glucose uptake and utilisation mainly by 
stimulation of the GLUT4 receptor in muscle and adipose tissue. This receptor is 
intracellular and normally cycles between the plasma membrane and vesicular 
compartments. Insulin stimulates the translocation of a pool of GLUT4 to the plasma 
membrane through a process of targeted exocytosis. The rate of glucose transport into fat 
and muscle cells is controlled by the concentration of GLUT4 at the cell surface and the 
duration of the receptor at this site (Tessin et al 1999).
Insulin Clearance
Normal insulin secretion is essential for the maintenance of plasma glucose concentration. In 
normal physiology insulin is released from the Beta cells in the islets of Langerhans into the 
portal circulation which flows directly to the liver. The liver extracts 50 to 60% of insulin 
secreted without ever reaching the systemic circulation (Field 1973, Ishida et al 1983, 
Polonsky et al 1983, Chap et al 1987) although this varies under different conditions. The 
kidney removes approximately 50% of peripheral insulin, 50% of circulating pro insulin and 
70% of C peptide by glomerular filtration (Rabkin and Kataji 1983, Rabkin et al 1984). This 
occurs by two mechanisms: glomerular filtration and proximal tubular reabsorption and 
degradation. In both hepatic and renal clearance the insulin is removed by receptor binding 
and internalisation into endosomes where degradation is initiated.
Glucose Regulation
Glucose Transport and Peripheral Glucose Uptake
Insulin affects many cellular systems including: transport o f molecules across the plasma 
membrane, levels of cyclic nucleotides, activities of key enzymes in intermediary 
metabolism, rates of protein synthesis and degradation, rates of DNA and RNA synthesis 
including specific gene expression and cellular growth and differentiation.
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In most mammalian tissues glucose is taken up via transport systems that display saturation 
kinetics. The intracellular glucose concentration is normally lower than the extracellular 
glucose concentration, and glucose is transported down its concentration gradient by 
facilitative diffusion across the cell membrane which is a rate limiting step in glucose 
disposal (Britton 1964). Glucose transport is mediated through solute carriers called the 
GLUT family of facilitative glucose transporters. Currently there are 13 members of this 
family GLUT1-12 plus the myo-inosotol transporter HMIT1. The best understood are 
GLUT 1-4.
The GLUT1 transporter is responsible for basal glucose uptake, the GLUT2 isoform is 
primarily expressed in the liver and (3 cell and has a relatively low affinity for glucose, 
GLUTS has the highest affinity and is expressed during fetal development and in adult 
neurons and finally GLUT4 protein is predominantly restricted to fat and muscle and is 
responsible for insulin stimulated uptake (Khan and Tessin 2002). The GLUT 1-3 
transporters are not insulin sensitive but the primary effect of insulin on peripheral glucose 
uptake is to stimulate translocation of the glucose transporter GLUT4 from an intracellular 
pool to the surface of the cells primarily in skeletal muscle, adipose tissue and heart 
(Zorzano et al 1998).
Endogenous Glucose Production
Glucose levels after a meal are determined by the ability of insulin to decrease endogenous 
glucose production (EGP) and to increase peripheral glucose uptake (PGU). Circulating 
plasma glucose in the fed state is mainly derived from the splanchnic bed. In the fasting state 
glucose is produced by the liver (EGP) and kidney by two processes, glycogenolysis and 
gluconeogenesis. To function effectively as a source of fuel and to supplement the energy 
supplied by muscle and splanchnic organs, glucose is normally released into the circulation 
of humans when fasted overnight at a rate of 10-11 pmol/Kg/min (Gerich 1993). After a 
prolonged fast the kidney has been shown to contribute up to 25% of EGP (Gerich et al 
2001). Nuclear magnetic resonance spectroscopy examining the change in hepatic glycogen
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content in overnight fasted volunteers has shown that net hepatic glycogenolysis occurs at a 
rate of approximately 5.5 pmol/Kg/min and accounts for 45 ± 6% of all glucose released 
into the circulation when measured isotopically (Peterson et al 1996). If  fasting is prolonged 
to 24 to 48 hours then hepatic glycogen content falls and gluconeogenesis becomes the sole 
source of glucose production (Rothman et al 1991).
Glycogenolysis involves the breakdown of glycogen to glucose-6-phosphate and then 
hydrolysis by glucose-6-phosphatase to glucose. Gluconeogenesis is the biosynthesis of new 
glucose from pyruvate, lactate, glycerol and the amino acids alanine and glutamine. Only the 
liver and kidneys contain glucose-6-phosphatase so the breakdown of hepatic glycogen 
releases glucose whereas glucose from the breakdown of muscle glycogen is metabolised to 
lactate. Lactate from muscle and other tissues such as blood cells and the renal medulla (via 
glycolysis of glucose) can be absorbed by the liver and kidney which are capable of 
gluconeogensis and used to generate glucose.
Glucose Oxidation
Glucose taken up by the cells is stored as glycogen or undergoes glycolysis to pyruvate 
which can be reduced to lactate, transaminated to alanine or converted to acetyl coenzyme 
A. Acetyl CoA can be oxidised to CO2 and H2O through the tricarboxylic acid cycle, 
converted to free fatty acids, utilised for ketone body synthesis (acetoacetate and (3- 
hydroxybutyrate) or cholesterol synthesis (in the liver and steroid synthesising tissues). The 
Cori cycle is the cycling of lactate by red blood cells and muscle during anaerobic 
respiration and the glucose alanine-cycle (muscles produce alanine and lactate during times 
of decreased oxygen), produces glucose in the liver. (Felig 1973).
Brain and muscle are the major tissues for glucose oxidation whereas adipose tissue, 
splanchnic tissues and to some extent muscle are geared towards storage. The glycolysis 
pathway where glucose is broken down to pyruvate and lactate is illustrated in Figure 4. 
The steps where insulin or glucagon has an effect by causing phosphorylation or 
dephosphorylation of the enzyme have been shown.
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Figure 4: The Glycolysis Pathway showing the effects of insulin and glucagon on the 
enzymes involved and PEPCK (phosphoenolpyruvate carboxykinase) (Umpleby 1986). 
GLUT is representing glucose transporters.
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Glucose Sensing and homeostasis
The regulation of plasma glucose is of vital importance for the brain which uses glucose as 
its obligate energy supply. Other organs can oxidise fatty acids as an alternative fuel supply 
to glucose. The brain cannot synthesise glucose or store glycogen for more than a few 
minutes and has high energy requirements at around 1.3 pmol/Kg/min in the presence of 
insulin (Bingham et al 2002). This facilitated diffusion of glucose from blood to the brain 
depends on arterial glucose concentration and control of this is vital to survival. There is 
evidence that the brain is able to metabolise ketones and lactate, but it is only able to do this 
at supraphysiological levels which only occur after prolonged fasting (Veneman et al 1994, 
Maran et al 1994, Amiel et al 1991).
Normally the plasma glucose concentration is maintained between 4.0 and 7.0 mmol/1. This 
is despite large changes in glucose influx from the gastrointestinal tract and glucose 
consumption e.g. exercise. In the fasting state the normal range for plasma glucose is 4.0 to 
6.0 mmol/1, the mean arterialised venous glycaemic threshold for a decrease in insulin 
secretion is 4.5 mmol/1 (Cryer et al 2003). The renal threshold for glucose is around 10 
mmol/1; with all the glucose below this level reabsorbed leaving urine glucose free under 
usual circumstances. In the 4 to 6 hour interval after eating, rates of glucose use are 
approximately 2.6 pmol/kg/min and at least 50% of whole body glucose use is a result of 
non insulin dependent uptake by the brain. Insulin sensitive tissues (muscle, adipose) 
account for less than 30 to 50% of overall glucose use (Bolli and Fanelli 1999). If fasting 
continues arterial glucose concentrations decrease to approximately 3.4-3.7 mmol/1 which 
can be maintained for several weeks (Owen and Reichard 1971).
Glucose sensing occurs in the brain, pancreas and liver. Evidence exists that the brain is of 
major importance in glucose sensing (Biggers et al 1989, Frizzell et al 1993, Ritter et al 
1981, Ritter et al 2000) with glucose sensing neurons in the ventromedial hypothalamus 
(VMH) and the brain stem where they can either be stimulated or inhibited by a rise in 
glucose (Song et al 2001). In the pancreas the P cell senses falling blood glucose which
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enters the beta cell via the GLUT2 receptors and facilitated diffusion. This leads to a 
decrease in intracellular ATP which opens K a t p  channels, leading in turn to cell membrane 
hyperpolarisation and decreased insulin secretion. (Aguilar-Bryan et al 2001). There is also 
recent interest in portal vein sensing of hypoglycaemia and its contribution to the counter- 
regulatory response. Normalising portal vein glucose concentration has been shown to 
suppress the sympathoadrenal (sympathetic neural and adrenomedullary) response under a 
number of hypoglycaemic conditions (Matveyenko and Donovan 2006).
Hypoglycaemia and Counterregulation
The sensing of decreasing glucose concentration outlined above leads to the decreased 
secretion of insulin which leads in turn to a rise in hepatic glucose production by a reduction 
in the suppression of hepatic glucose output. If  the blood glucose concentration continues to 
decline counter-regulatory hormones are stimulated, there is a hierarchy in their response. 
The a  cells in the islets of Langerhans in the pancreas secrete glucagon into the portal vein, 
secretion occurs in response to hypoglycaemia and is inhibited when the glucose 
concentration reaches normal levels (4-6 mmol/1) (Gerich et al 1974, Olsen et al 2005). This 
is considered to be the most important first line defence against hypoglycaemia in normal 
physiology (Rosen et al 1984, Rizza et al 1979).
Glucagon activates glycogenolysis and to a lesser degree gluconeogenesis so increasing 
hepatic glucose production. The glucose threshold for glucagon and adrenaline secretion is 
3.6 - 3.9 mmol/1 and neuroglycopenic symptoms and cognitive impairment occur at a 
threshold of 2.8-3 mmol/1 (Cryer et al 2003). The other major counter-regulatory hormones 
are noradrenaline, cortisol and growth hormone. The glycaemic thresholds for secretion of 
noradrenaline, cortisol and growth hormone are between 3.6-3.9 mmol/1 in arterialised 
venous samples (Cryer 1997, Cryer et al 2003). It is important that the counterregulatory 
hormone response occurs so that the symptoms of hypoglycaemia, sweating, palpitations 
and shaking, occur well before any neuroglycopenic symptoms and ultimately cognitive 
decline occurs providing protective warning signs of a declining glucose concentration.
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Adrenaline is secreted by the chromaffin cells of the adrenal medulla. Release is stimulated 
by hypoglycaemia and it stimulates hepatic and renal glucose production and limits glucose 
utilisation via a and (3 adrenoreceptors. It increases gluconeogenic substrates such as amino 
acids, lactate and glycerol and becomes critical in glucagon deficiency acting within minutes 
to raise plasma glucose (Cryer 2003). Adrenaline infusions which mimic the physiological 
response to hypoglycaemia increase renal glucose production whereas glucagon infusions 
have little effect at the kidney in the post absorptive state (Stumvoll et al 1995, 1998). The 
stimulation of lipolysis contributes to counter regulation via non esterified fatty acids 
(NEFA) which exert their counter regulatory effect mainly at the liver (Fanelli at al 1993). 
NEFA stimulate hepatic gluconeogenesis and suppress glucose oxidation and use. 
Noradrenaline concentration in plasma rises less, but it acts though the same pathways as 
adrenaline with similar effects. It also inhibits insulin secretion and stimulates glucagon 
synthesis.
Growth hormone and cortisol act more slowly to correct hypoglycaemia, the effects of 
growth hormone in hypoglycaemia take longer than two hours to take effect (MacGorman et 
al 1981). Growth hormone increases glucose production and also limits its use. Prevention 
of the growth hormone response to hypoglycaemia can result in severe hypoglycaemia even 
when catecholamines are increased (De Feo at al 1989). Cortisol is also important in 
counter-regulation, when a cortisol response is prevented experimentally it has resulted in a 
decrease in hepatic glucose production, an increase in peripheral glucose uptake and a 
reduced plasma NEFA concentration resulting in greater hypoglycaemia despite an increase 
in adrenaline (De Feo et al 1989).
In summary all counter regulatory responses to hypoglycaemia increase hepatic glucose 
output by working in combination with the stimulation of lipolysis. Some also decrease 
peripheral glucose uptake. In normal physiology these defence mechanisms are appropriate 
as insulin is released into the portal circulation and has its first effects at the liver, and the 
liver is essential in the production of glucose to support brain metabolism.
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IGF 1 and IGFBP1
Some of the action of growth hormone is mediated by IGF peptides (insulin like growth 
factors). Growth hormone raises blood glucose whereas IGF peptides lower blood glucose. 
The IGF peptides circulate in plasma as a complex with insulin like growth factor binding 
proteins (IGFBP). This extends the half life of the IGF peptides and transports them to target 
cells. In diabetes GH is abnormally increased as a result of reduced portal insulin resulting 
in impaired hepatic IGF-1 generation and therefore feedback promoting growth hormone 
secretion (Holt et al 2003). IGF 1 administration increases glucose uptake and inhibits 
glucose production in subjects with and without diabetes (Muzumdar et al 2006).
Circulating IGFBP levels reduce the glucose lowering potential of systemically administered 
IGF 1 and hepatic production and circulating levels of IGFBP 1 are decreased in 
hyperinsulinaemic clamps in type 1 diabetes. This suppression of IGFBP 1 production by 
insulin is thought to be a good marker of hepatic insulin action (Ekstrom et al 2007). 
IGFBP 1 levels rise in hypoglycaemia induced by insulin with levels peaking 1-2 hours after 
the glucose nadir, possibly by inhibiting the metabolic actions of IGF 1. This would support 
a role for IGFBP 1 in the counterregulation of hypoglycaemia in addition to it being a good 
marker of insulin action at the liver (Lee et al 2003).
Fat and Lipid metabolism
Plasma lipids exist as free cholesterol, cholesterol ester, triglycerides (glycerol and fatty 
acids) and phospholipids (triglycerides and a phosphate derived group). They are transported 
as lipid protein complexes and these are classified according to their density: High density 
lipoprotein (HDL), intermediate density lipoprotein (IDL), low density lipoprotein (LDL), 
and very low density lipoprotein (VLDL). NEFA are released from triglycerides in VLDL 
and chylomicrons through the action of lipoprotein lipase (LPL). In adipose tissue high 
levels of glucose and insulin promote the conversion ofNEFA to triglyceride for storage. 
Insulin stimulates LPL activity and NEFA estérification through the formation of glycerol 
phosphate and decreases NEFA release through the inhibition of hormone sensitive lipase 
(Strafors et al 1987). NEFA and not glucose are the main endogenous energy source for
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unstimulated P cell (Malaise et al 1983) and provide energy in the fasted state to other 
tissues that can have differing levels of LPL activity (heart, muscle, adipose tissue).
Release ofNEFA and glycerol from adipose triglyceride stores occurs in uncontrolled 
diabetes and insulin deficiency. Lack of insulin as in type 1 diabetes causes increased 
hormone sensitive lipase activity, which increases triglyceride hydrolysis and NEFA 
delivery to the liver. NEFA are then oxidised in mitochondria in the liver, giving rise to the 
products of ketogenesis, acetoacetate, p-hydroxybutyrate and acetone. The accumulation of 
these causes ketoacidosis (figure 5)
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Hypoglycaemia and type 1 diabetes.
The profound effects of severe hypoglycaemia on the brain were recognised and described 
soon after the discovery of insulin (Banting et al 1923). Hypoglycaemia occurs when the 
rate of glucose efflux from the circulation exceeds that of glucose influx into the circulation. 
Iatrogenic hypoglycaemia is the rate limiting step for tight control of type 1 diabetes. 
Aggressive attempts to achieve glycaemic control increase the risk of severe, temporarily 
disabling hypoglycaemia more than three fold as documented in both the Diabetes Control 
and Complications Trial (DCCT) and the Stockholm Diabetes Intervention Study (Reichard 
and Pihl 1994). Insulin injected in the periphery exerts its effect in an unphysiological 
manner compared to that of normal physiology when insulin is released into the portal vein 
as outlined above.
The risk of hypoglycaemia and the effects on cognitive function are a major impediment to 
gaining good control for people with diabetes. Striking the balance o f acceptable blood 
glucose control verses hypoglycaemic events is a difficult one. Fear and past experience of 
hypoglycaemia is associated with poor metabolic control in people with diabetes (Cox et al 
1987, Irvine and Saunders 1989). It is the loss of normal social behaviour, and if  untreated 
or unrecognised, loss o f consciousness that is feared by patients with type 1 diabetes 
(Pramming et al 1991, Thorsteinsson et al 1991). Studies have estimated that people with 
type 1 diabetes can experience approximately 2 episodes of symptomatic hypoglycaemia per 
week, approximately 43 episodes per year and an episode of severe hypoglycaemia about 
once or twice a year (DCCT 1993, Reichard et al 1991, MacCleod et al 1993, Donnelly et al 
2005). This risk increases with a history of hypoglycaemia and number o f years of insulin 
treatment (Donnelly et al 2005, Cryer et al 2003).
Asymptomatic episodes of hypoglycaemia may occur in up to 10% of a 24 hour period in 
people with diabetes (Boland et al 2001, Gross et al 2001). The more intensive and tighter 
the control the lower this threshold for counter-regulation of hypoglycaemia can become 
(Amiel et al 1988). This can be a particular problem during sleep; nocturnal hypoglycaemia 
is not unusual affecting up to 50% of adults and 78% of children with diabetes (Allen & 
Frier 2003). Recognition of symptoms o f hypoglycaemia occurring during sleep and
39
counter-regulatory responses may be diminished (Banarer and Cryer 2003) and this can have 
a carry-over effect into recognition and counter-regulation o f hypoglycaemia during the next 
24 hours (Veneman et al 1993, Davis et al 1997). Just one episode o f hypoglycaemia can 
diminish further symptomatic and counter-regulatory responses in subjects without diabetes 
(Heller and Cryer 1991).
To identify an insulin treatment that could control blood sugar in a predictable, reproducible 
way that protected in some way against the risk o f hypoglycaemia would be ideal.
Hypoglycaemia Symptoms, Awareness and Counterregulation and in Type 1 Diabetes
In people without diabetes the normal response to reducing circulating glucose is to reduce 
endogenous insulin secretion and counter-regulatory mechanisms are triggered to increase 
glucose concentration. The hierarchy of response to hypoglycaemia and the levels at which 
this occurs are reproducible and similar in patients without diabetes (Cryer et al 2003) but 
have been shown to shift to higher thresholds in poorly controlled diabetes (Boyle et al 
1988, Amiel et al 1988, Cryer et al 2003) and to lower thresholds in those with tightly 
controlled diabetes (Amiel et al 1988, Cryer et al 2003) In type 1 diabetes no reduction in 
circulating insulin can occur (Sacca et al 1979) and there is a failure of glucagon response 
(Gerich et al 1973, Bolli et al 1983). The mechanism of the loss o f the glucagon response is 
not entirely understood and glucagon secretory responses to other stimuli (other than 
hypoglycaemia) are intact suggesting it is linked to the lack of beta cell secretion of 
endogenous insulin, the “intraislet insulin hypothesis” (Fukuda et al 1988, Banarer et al 
2002, Nyaz et al 2005).
As the first two defences to hypoglycaemia are lost the next in line is the adrenaline 
response which is considered the most important when glucagon secretion is deficient 
(Rizza et al 1979, Rosen et al 1984) which can be the case early on in type 1 diabetes (Bolli 
et al 1983). The adrenaline response can also be impaired in type 1 diabetes with the glucose 
concentration at which the adrenaline response is triggered reset to a lower level (Amiel et al 
1988, Bolli et al 1983, Dagogo-Jack et al 1993). In type 1 diabetes the combined deficiency 
of glucagon and adrenaline creates a much greater risk of hypoglycaemia particularly when
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aiming for tight glucose control (Bolli et al 1984, White et al 1983). This in turn leads to 
hypoglycaemia unawareness over time as the warning signs o f hypoglycaemia are lost 
leading to a higher risk of more severe iatrogenic hypoglycaemia (Gold et al 1994).
After a number o f years of tight glucose control in type 1 diabetes, hypoglycaemia 
unawareness can develop so the threshold for symptomatic response is lowered from 3.6 -  
3.9 mmol/1 to 2.4 mmol/1 (sometimes less) and the change in glucose level triggering 
counter-regulation falls by over 1 mmol/1 (Amiel et al 1988). In addition prior experience of 
hypoglycaemia or hyperglycaemia can alter the glucose level at which autonomic counter­
regulation occurs (Davis et al 1992, Maran et al 1995, Cranston et al 1994). This can leave 
patients with type 1 diabetes with previous recent hypoglycaemia at risk for severe 
hypoglycaemia with loss of warning symptoms (Amiel 1998). This hypoglycaemia 
unawareness is associated with a six fold increase in risk o f iatrogenic severe hypoglycaemia 
(Geddes et al 2008).
Hypoglycaemia-associated autonomic failure (HAAF) is a description of the phenomenon 
described above of iatrogenic hypoglycaemia causing loss of awareness by reducing the 
autonomic sympathetic neural and adrenomedullary response and therefore symptom 
response and defective counter-regulation (absent glucagon, defective adrenaline secretion) 
(Cryer et al 2003). This can create a vicious cycle of hypoglycaemia. Avoidance o f 
hypoglycaemia for 2-3 weeks can reverse hypoglycaemia unawareness and improves the 
adrenaline response but not the glucagon response (Cranston et al 1994, Fanelli et al 1994, 
Dagogo-Jack et al 1994).
Other factors that affect sensitivity to declining glucose and counter-regulation include prior 
exercise (Ertl & Davis 2003). Studies have reported a reduction of approximately 50% in the 
neuroendocrine and metabolic responses in people with and without type 1 diabetes after 
hypoglycaemia (using the hyperinsulinaemic hypoglycaemic clamp method) (Davis et al 
2000, Galasetti et al 2001). The effect of moderate exercise on hypoglycaemia awareness 
and counterregulation can last between 6 and 15 hours afterwards which also means its 
effects are often nocturnal (MacDonald 1987, Tsalikian et al 2003, Sandoval et al 2004).
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Experimental Models for Studying Hypoglycaemia.
Hypoglycaemia, the perception and recognition of symptoms, counter-regulation and effects 
on cognitive function in type 1 diabetes have been extensively studied. Initial methods used 
intravenous boluses of insulin leading to a rapid fall and then rise in blood glucose, so it was 
difficult to pinpoint a level at which cognitive function was affected (Russell and Rix-Trot 
1975). Following this study a different methodology was tried where insulin was infused 
intravenously, lowering blood glucose in plateaus, however it was technically difficult as 
adjusting insulin infusion rates on their own made it difficult to control and reproduce the 
glucose level (Pramming et al 1986). The hyperinsulinaemic glucose clamp was developed 
using stable insulin concentrations with glucose infused at differing rates to maintain blood 
glucose at a fixed level (De Fronzo et al 1979).
This glucose clamp methodology was adapted to lower glucose in a series o f steps into 
controlled hypoglycaemia allowing a specific glucose concentration at which counter­
regulation and cognitive function are affected (Amiel et al 1987). This situation is not 
physiological as the responses are being obtained during fixed hyperinsulinaemia and 
enforced continuing hypoglycaemia which is unlike the clinical use of insulin and iatrogenic 
hypoglycaemia in type 1 diabetes. It is also possible that the high concentrations of insulin 
that exist in the clamp could modify brain function as pharmacological doses could cause a 
rise in cerebral blood glucose and the physiological response may be different to those that 
occur during insulin therapy (Heller and Macdonald 1996). This method has however 
allowed measures of awareness, neurohumoral responses and cognitive function to be taken 
to determine the threshold at which different responses to hypoglycaemia occur (Amiel et al 
1987).
The rate o f fall of glucose concentration in hypoglycaemia
In one study using hypoglycaemic hyperinsulinaemic clamps with normal subjects and those 
with type 1 diabetes in the fasting state a nine fold difference in the rate of fall o f blood 
glucose did not show any substantive differences in the counterregulatory response o f GH, 
cortisol and glucagon in subjects with diabetes. The plasma glucose level at which
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adrenaline was released was variable but was not substantively different between groups. 
These results suggested that the counter regulatory hormone response was triggered by the 
level of hypoglyceamia and not the rate of fall o f glucose (Amiel et al 1987).
The rate of glucose concentration decline has also been examined in the post prandial state 
in subjects with type 1 diabetes using glucose clamp methodology. The responses to 
hypoglycaemia both in perception of symptoms, counter-regulation and cognitive 
dysfunction were examined with a fast fall (a rate o f decline of 0.1 ± 0.003 mmol/1 /min (30 
min)) and slow fall (0.03 ± 0.0001 mmol/l/min (90 min)) compared to euglycamic control. 
No difference in symptoms was observed but with a fast fall there was a greater 
deterioration in cognitive function and less activation o f the counter-regulatory response 
(adrenaline and noradrenaline) in the post prandial state when compared to a slow fall 
(Fanelli at al 2003).
Cognitive Function Tests in Hypoglycaemia
In subjects with diabetes and healthy volunteers the neuro-endocrine response begins before 
that o f detectable cognitive impairment (Amiel et al 1987, Boyle et al 1988). There are 
several different tests o f cognitive function used experimentally that have different degrees 
o f sensitivity to a declining glucose level. The more commonly used tests and the threshold 
of deterioration are outlined below.
The four choice reaction time and Stroop reading tests show a deterioration between glucose 
concentrations o f 2.8 to 3.0 mmol/1 in individuals with and without diabetes (Boyle et al 
1994, Maran et al 1995). The four choice reaction time test involves a computer screen 
which randomly displays a dot in one of four possible fields. The subject responds by 
pressing the corresponding positioned key on a keypad and results are recorded for accuracy 
and speed (Wilkinson and Houghton 1975). The Stroop reading test involves showing a card 
with a word written in coloured ink, naming the colour of the ink the word is written in 
rather than the word itself is the correct response and requires more mental effort (Stroop 
1935 PhD thesis).
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Other tests include simple motor function i.e. finger tapping (pressing a computer key as fast 
as possible for 10 seconds and recording the time taken) which is less sensitive and 
deteriorates at 2.3 mmol/1 (Hopkins et al 1998). Short term memory tests (simple recall o f a 
list or objects) and trail tests (drawing a line between circles, each containing a letter or 
number, to connect them in the correct sequence) show a decline at about 3.0 mmo/1 and 2.5 
mmol/1 respectively (Boyle et al 1994, Hopkins et al 1998, Fanelli et al 1998). The effects of 
tight control on cognitive function seems to depend on the test being studied. The four 
choice reaction time test seems to have a fixed threshold in hypoglycaemia unaware patients 
compared to those who are aware (Amiel 1988).
The difficult balance o f good glycaemic control vs. hypoglycaemia in type 1 diabetes
The importance of good glycaemic control in type 1 diabetes was demonstrated by the 
DCCT study (Diabetes Control and Complications Trial). The DCCT was a study in 1441 
subjects with type 1 diabetes with a mean follow up of 6.5 years. They were randomised to 
either intensive control (with basal bolus regime and strict targets) or conventional 
treatment. Those in the intensive group had a mean HbAlc (glycosylated haemoglobin) of 
7.1% whereas those in the conventional treatment group had an HbAlc of 9.0%. There was 
a lower rate of complications in the intensive group with a reduction in: the risk of 
retinopathy (45%), development of microalbuminuria (35%) and clinical neuropathy (60%). 
For every 10% reduction in HbAlc there was about 35% risk reduction of retinopathy, 25- 
44% risk reduction for nephropathy and 30% risk reduction for neuropathy. All this was at 
the expense of increased frequency of hypoglycaemia three times that observed in the less 
well controlled group. Cardiovascular disease was decreased in the intensively treated group 
but because it was a relatively short period o f follow up and with a low event rate the 
reduction did not meet statistical significance.
The EDIC/DCCT (Epidemiology in Diabetes Interventions and Complications) study group 
followed on from the DCCT study and continued with 96% of the original cohort. Type 1 
diabetes is associated with a greatly increased risk (approximately 10 times) of
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cardiovascular disease compared to an age matched population (Laing et al 2003). At the 
end of the DCCT (after 6.5 years o f follow up) the conventional group was offered intensive 
treatment and the difference in the mean HbAlc narrowed over the next 11 years of follow 
up (HbAlc 8.0%± 1.2% and 8.2 ± 1 . 2  %). The primary outcome was a definite cardiac 
event. Intensive treatment was associated with a 42% reduction in risk compared to 
conventional treatment, the risk o f myocardial infarction, stroke or death from 
cardiovascular disease was reduced by 57% with intensive treatment although the total 
number of events remained low (Nathan et al 2005).
These trials are accepted to show the benefit o f good control with intensified insulin 
regimes, the risk o f hypoglycaemia remains a significant barrier to achieving this. As 
outlined in the introduction hypoglycaemia causes significant morbidity, is sometimes fatal, 
compromises awareness and counterregulatory responses and can cause a vicious cycle of 
hypoglycaemia and therefore interferes in achieving this goal.
A recent working party on the definitions of hypoglycaemia established that the term 
“severe hypoglycaemia” means bystander assistance is required (including seizure or coma), 
“symptomatic hypoglycaemia” is a reading of below 3.9 mmol/1 with symptoms, 
“asymptomatic hypoglycaemia” a plasma glucose concentration of <3.9 mmol/1 without 
symptoms and “probable symptomatic hypoglycaemia” is symptoms without blood glucose 
readings and finally “relative hypoglycaemia” which is symptoms of hypoglycaemia with 
plasma glucose greater than 3.9 usually experienced in poor control (American diabetes 
association 2005). These definitions are important to unify terms in research studies.
In terms o f reducing the clinical risk of hypoglycaemia a number of strategies and 
approaches have been tried. The aim is to replace insulin in as physiological manner as 
possible. Normal physiological secretion is shown below (Figure 6). This represents a steady 
basal secretion with increased pulses with carbohydrate intake.
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Figure 6: Physiology of glucose homoeostasis in subjects without diabetes (Rossetti et al 
2008 b).
Insulin Therapy
Insulin analogues, both short and long acting, have been the focus o f development with the 
aim that their improved action profile will result in a more physiological insulin profile. 
Insulin molecules have a tendency to self-aggregate into hexameric complexes and these 
clusters must dissociate into dimers and monomers to diffuse through interstitial fluid, 
penetrate the capillary wall, and enter the bloodstream (Guerci et al 2005). Transposing or 
substituting amino acids produces insulins that are less likely to self aggregate and remain 
monomeric at high concentrations; therefore they are absorbed more rapidly. These insulin 
analogues include insulin lispro, insulin aspart and insulin glulisine which are short acting 
and insulin detemir and insulin glargine which are intermediate acting.
The “short acting” insulin that predated these short acting insulin analogues had an onset o f 
action 30 minutes to 1 hour after injection and peaking at 2-4 hours (Howey et al 1994) 
which meant in theory injecting 30 minutes to 1 hour before eating which was not practised
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by most people (Heinemann 1995). Post prandial initial hyperglycaemia occurred due to 
delayed absorption and a relative excess o f insulin over and above that which was the 
physiological norm, then sometimes resulting in the need to snack or increased risk o f 
delayed hypoglycaemia. The short acting insulin analogues are absorbed more quickly 
achieving peak concentrations within approximately half the time and twice as high as 
regular insulin which leads to lower glucose values after meals (Howey 1994, Heinemann et 
al 1996).
Normal postprandial values
(Mean±SD, n=23)
*-# S c injection of soluble insulin 
in diabetic subjects 
(Mean ± SEM, n=20)
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(Mean ± SEM, n=10)
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Figure 7: Comparison of pharmacokinetics after subcutaneous injection of human 
insulin and rapid acting insulin analogs (Rossetti et al 2008 b).
This action profile would lead to the aim that these analogues have an action nearer that o f 
normal physiology and therefore improved control (Figure 7). They have not entirely lived 
up to this aim. A recent Cochrane review (Siebenhofer et al 2006) identified that the 
weighted mean difference o f HbA lc was -0.1% in favour o f short acting insulin analogue 
and the overall mean o f hypoglycaemia events per patient month was -0.2% for analogues in 
comparison to regular insulin in type 1 diabetes. The incidence o f severe hypoglycaemia in
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studies in the same review ranged from 0 to 247.3 (median 21.8) episodes per 100 person 
years for insulin analogues compared to 0 to 544 (median 46.1) for regular insulin.
Long Acting Insulin
In the early stages o f insulin development insulin treatment consisted of just short acting 
insulin before meals. Mixing insulin with different substances has been tried in order to 
prolong its action including gum arabic (1923), lecithin (1923) and oil suspensions (1925) 
(Rosskamp and Park 1999). These attempts were mostly unsuccessful because o f poor 
stability or side effects at the local injection site.
The first successful long acting insulin was Neutral Protamine Hagedom insulin (NPH) 
(Hagedorn 1936) with an action roughly twice as long as unmodified insulin. This was 
achieved by forming a complex between the fish protein protamine, zinc and insulin. It 
contains two zinc atoms, making it less soluble at neutral pH. Proteolytic enzymes degrade 
the protamine after subcutaneous injection and the insulin is absorbed slowly.
The addition of further zinc ions to insulin caused a crystalline suspension to form which 
also significantly protracted the length of action of insulin (called Lente containing ten times 
the amount of zinc compared to NPH insulin (Hallas-Moller 1956)). These are not in routine 
clinical use now, the companies that manufacture the Lente and Ultralente insulins (both 
human and animal) withdrew them due to low product use around the time that insulin 
analogues were marketed.. Until relatively recently these were the choices for long acting 
preparations. However along with NPH (Insulatard), Insulin Detemir and Insulin Glargine 
have provided an additional choice each with slightly different properties.
An ideal long acting insulin should mimic physiological basal secretion, be a once daily 
injection, be peakless, be reproducible in the same subject and between subjects and soluble 
at neutral pH. It should cover between meals and periods o f fasting such as overnight.
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NPH Insulin
NPH insulin action has been described as having a peak of action of around 3-8 hours after 
injection and a variable absorption on a day to day basis (Binder et al 1984, Home 1999, 
Lepore et al 2000).Its duration of action is 14 ± 3 hours and to provide 24 hour cover needs 
to be injected twice daily (Lepore et al 2000). Variations in the glucose lowering effect vary 
from 18 to 68% in clinical trials (Heinemann 2000, Heise et al 2004). Factors that can 
contribute to day to day variation include the size of the dose, injected volume, insulin 
concentration and changes in blood flow to the tissue that it is injected (Binder 1984). In 
addition patients with diabetes do not always follow the correct mixing procedure which will 
also contribute to variability (Jehle et al 1999).
The peak of action o f NPH insulin which is usually injected before bed time can mean that 
there is over insulinisation in the middle of the night with risk o f hypoglycaemia and not 
enough residual insulin action in the morning resulting in fasting hyperglycaemia (Binder et 
al 1984, Lepore at al 2000).This peak in its action profile and day to day variability can lead 
to increased hypoglycaemia without obvious explanation, a common problem in clinical 
practice.
Long acting insulin analogues 
Insulin glargine
Insulin Glargine is an analogue produced by recombinant DNA technology. Amino acid 
changes shift the isolelectric point from 5.4 to 6.7 which reduces the solubility o f Glargine at 
physiological pH (it is most soluble at acidic pH) and stabilises the hexamer delaying its 
dissociation into monomers (Ratner et al 2000, Hartman 2005). It also contains small 
amounts of zinc, which delays and prolongs absorption (Hilgenfeld et al 1992, Owens et al 
2000). In clinical trials in healthy volunteers euglycaemic clamps have shown a more 
constant metabolic activity and without a pronounced peak and a metabolic action that 
persisted beyond 24 hours (measured to at least 30 hours) (Bolli and Fanelli 1999,
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Heinemann et al 2000). Similar results have been obtained in type 1 diabetes (Lepore et al 
2000). The site of injection does not seem to affect its absorption (Owens et al 2000) and 
neither does the effect of exercise (Peter et al 2005). There has been clinical concern about 
the risk of accumulation of glargine although a multiple dose study has not shown evidence 
o f this over 12 days (Heise et al 2002).
In clinical trials using insulin glargine as part o f a basal bolus regimen compared to once or 
twice daily NPH for varying periods there was a greater reduction in fasting blood glucose 
(Pieber et al 2000, Rosenstock et al 2000 (4 weeks each), Raskin et al 2000 (16 weeks) 
Ratner et al 2000 (28 weeks)), a lower variability in fasting blood glucose (Raskin et al 
2000, Ratner et al 2000), a lower frequency o f nocturnal hypoglycaemia (Pieber et al 2000 
(compared to once daily NPH not twice daily), Ratner et al 2000), and a reduction in HbAlc 
(-0.14% Peiber et al 2000).
Insulin Detemir
Insulin detemir is produced by a process including recombinant DNA technology using 
Saccharomyces cerivisiae and chemical synthesis. The molecular formula is C267H402N64S6 
and the molecular weight is 5916.9 Da. The amino acid residue at position B30 is omitted, 
and a 14-C fatty acid chain attached to position B29 (Figure 8). The molecule is lipophilic 
due to the fatty acid chain. By adding zinc to the formulation, the molecule is stabilized and 
hexamers are formed making it hydrophilic and thereby soluble in water (Kurtzhals et al 
1995, Markussen et al 1996).
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Schematic Structure of Insulin Detemir
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similar for the first 12 hours after which it decreased with insulin detemir, the median 
duration o f action being 24 vs. 17.5 hours (glargine vs. detemir pO.OOl) (Figure 9).
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Figure 9. A comparison o f the pharmacodynamics o f NPH insulin, insulin detemir and 
insulin glargine in type 1 diabetes (Porcellati 2007)
Are these observed differences with insulin detemir simply down to the improved glucose 
profile and predictability with reduced intra-subject variation or could there be another 
explanation?
The Endothelial Barrier
The endothelial barrier in capillaries is a membrane across which active and passive 
transport o f molecules take place. It is a barrier between blood, extracellular fluid and tissue 
cells. There are two continuous layers in the walls of the capillaries, the endothelium and the 
underlying basement membrane. For small molecules such as ions, water and gases, passage 
through these and equilibration happens rapidly (Hill 1928) but for larger molecules such as 
Y globulins and albumin this process is slower (Renkin 1964). Transport o f substances may 
also be facilitated by transmembrane transporters.
Endothelial cells differ in their permeability (Renkin 1964); those in the central nervous 
system including larger peripheral nerves and the retina and iris have the tightest gap 
junctions. Capillaries of muscle and skin in contrast have small openings in the junctions 
between cells which are non-restrictive. Endothelial cells of some capillaries have been 
shown to have a large proportion o f small vesicles and fenestrae (Wissig and Charonis 
1984). Vesicles have been shown to shuttle fluid across endothelial cells (Palade 1961) and 
can be bidirectional. Fenestrae are openings throughout the endothelial plasma membrane 
with a range o f pore diameters around 30-80nm closed by a delicate unilaminar diaphragm 
2-4nm thick (dem enti and Palade 1969).
The blood brain barrier is formed by brain endothelial cells and is extremely important for 
brain protection. Junctions between cells in brain capillaries are -50-100 times tighter than
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in peripheral microvessels. These tight junctions cause severe restriction of the paracellular 
(tight junctional) pathway for diffusion of hydrophilic solutes. This means that penetration 
across the brain endothelium is effectively confined to transcellular mechanisms. Small 
lipophilic molecules such as oxygen, CO2 and ethanol diffuse freely across the lipid 
membranes of the endothelium whereas small polar solutes needed for brain function are 
transported by a number o f specific carriers (e.g. GLUT-1 for glucose, L-system carrier LI 
for large neutral amino acids such as leucine) (Abbott 2002). Systemic insulin accesses the 
brain via an active, saturable, transendothelial transport across the blood brain barrier 
(Woods et al 2003).
In the liver the sinusoids are unique capillaries with open fenestrae without a diaphragm and 
lacking basal laminae first visualised via electron microscope (Wisse 1970). This is in 
contrast to fenestrae described in the kidney and pancreas (Braet et al 2005). The large gaps 
in the endothelial cell layer and absence o f a continuous basal lamina means no significant 
barrier exists between blood plasma in the sinusoid and the hepatocyte plasma membrane 
(Ross et al 2003). This is known as the “space of Disse” (the perisinusoidal space) (Gray 
1973, Reichen 1999). These open fenestrae which are arranged in sieve plates, measure 
150-175 nm in diameter, occur at a frequency of 9-13 per pm2 and occupy 6 -8 % of the 
endothelial cell surface, measured by scanning electron microscopy. They control the rate of 
flux of fluids, solutes and macromolecules between the sinusoids and the space o f Disse 
according to their size, charge and chemistry (Wisse et al 1985). The fenestrae are 
surrounded by an associated cytoskeleton ring (Braet et al 1995) with contractile bundles of 
actin and myosin seeming to regulate the diameter under the influence of intracellular 
calcium (Gatmaitan et al 1996). Liver sinusoid endothelial cells have high endocytotic 
capacity with numerous vesicles and receptor uptake of a wide variety o f substances from 
the blood (Smedsrod et al 1994).
Hepatic Insulinisation and the Endothelial Barrier.
In normal physiology insulin is released from the islets within the pancreas into the portal 
circulation which flows directly to the liver, a major insulin target organ. The liver extracts
53
up to 60% of the insulin delivered to it with the remainder dispersed into the systemic 
circulation (Chap et al 1987). In consequence hepatocytes are exposed to insulin 
concentrations 3-4 times higher than the other major targets for insulin (adipose tissue and 
muscle) and hepatic extraction is potentially important for control o f the circulating 
concentration o f the hormone. As a replacement therapy, insulin is delivered as a 
subcutaneous depot and absorbed into the systemic circulation through which it is 
distributed in approximately equal concentrations throughout the body. The normal 
portal/peripheral insulin gradient is lost resulting in a relative peripheral hyperinsulinaemia 
and underinsulinisation of the liver. This metabolic imbalance is inevitable with most 
existing insulin preparations and may contribute to both acute and chronic complications of 
diabetes.
Studies using a 14C-glucose tracer infusion of semisynthetic modified insulins and proinsulin 
in dogs suggested that these covalent insulin dimers may have a predominant action on the 
liver (Tompkins et al 1981, Shojaee-Moradie et al 1995). Later euglycaemic clamp studies 
using recombinant human proinsulin in healthy volunteers suggested that there was greater 
suppression of endogenous glucose production at the liver than stimulation of peripheral 
glucose uptake (Revers et al 1984, Glauber et al 1986, Galloway et al 1992). This difference 
in central and peripheral action could be explained by a difference in distribution or 
mechanism o f action. One theory is that the difference in molecular size of proinsulin 
(9390Da) compared to insulin (5807Da) could affect the rate of travel through the 
endothelium of the liver to the insulin receptor. Monomeric insulin analogues (e.g. B25 Asp, 
B9Asp and B27Glu, insulin aspart) are absorbed more rapidly from subcutaneous tissue 
through the capillary endothelial barrier in the reverse direction than native insulin at 
treatment concentrations in the dimeric and hexameric form (Brange et al 1988, Kang et al 
1991, Lindholm et al 1999); this would support this theory of the capillary endothelial 
barrier effect in the periphery. An insulin analogue bound to one or more plasma proteins 
may have greater access to hepatocytes than to peripheral target tissues.
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Figure 10: Schematic Representation of Albumin Binding of Insulin Detemir: Potential 
mechanism for differences in effect on the liver and periphery.
It has been proposed that insulin detemir because o f its protein binding may have a relatively 
greater effect at the liver compared to the peripheral target tissues when administered 
subcutaneously at least partially restoring the normal liver/peripheral gradient in insulin 
action (Figure 10). Additional support for this hypothesis comes from studies with a novel 
insulin analogue that binds to thyroid hormone binding proteins. Bl-thyroxyl insulin 
demonstrated a relatively greater effect on the liver compared to peripheral tissues (Shojaee- 
Moradie et al 2000) and clamp studies in subjects without diabetes showed that insulin 
detemir had a greater effect than a preparation o f human insulin on glucose metabolism in 
the liver and a lesser effect on peripheral tissues (Hordern et al 2005).
Is Detemir Hepatoselective?
It is possible that the unique properties o f insulin detemir, in particular the differences in 
weight gain observed that are independent o f glucose control (HbAlc) and the reduced 
hypoglycaemia in clinical studies, can be attributed to a more physiological action profile o f
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insulin detemir i.e. a greater action at the liver compared to the periphery due to being 
albumin bound. Weight gain associated with insulin use in type 1 diabetes can have 
undesirable effects such as increased blood pressure, increased low density lipoprotein and 
total cholesterol level, decreased high density lipoprotein and increased weight hip ratio, all 
markers o f cardiovascular risk (Purnell et al 1998). The mechanism behind why insulin 
detemir is associated with less weight gain in clinical studies is not clear. Theories include 
less defensive snacking due to reduced risk of hypoglycaemia and the more reproducible 
glucose lowering profile of insulin detemir. Additional theories include that if  it does have a 
hepatoselective action that hepatic gluconeogenesis is suppressed without stimulating 
lipogenesis in the periphery or that it may be more effective than human insulin in 
communicating satiety signals in the central nervous system (Hermansen and Davies 2007).
The normal hierarchy of physiological responses to hypoglycaemia are lost in type 1 
diabetes where insulin therapy delivered subcutaneously results in an excess o f insulin in the 
periphery and relative under insulinisation of the liver. It is possible that counter-regulatory 
mechanisms would more adequately correct hypoglycaemia occurring with less 
inappropriate insulin stimulation of peripheral glucose uptake. The counter-regulatory 
hormone response to insulin acts predominantly on stimulating EGP either directly or 
through stimulation of lipolysis as previously discussed.
Hypothesis
It was hypothesised that insulin detemir is hepatoselective. If  insulin detemir has a more 
specific effect on the liver the threshold for release o f counterregulatory hormone response 
will be earlier than with human insulin preparations, and thus the awareness profile will be 
different. An insulin with a greater effect at the liver would make it easier to cope with 
minor hypoglycaemic episodes as the counterregulatory hormones have a greater effect on 
the liver than on the periphery.
56
Aims
• This study aimed to investigate the onset and symptoms o f a hypoglycaemic episode 
following one single subcutaneous dose of insulin detemir and NPH insulin on 
separate occasions and the fall in glucose concentration.
• It aimed to investigate whether the lower number of hypoglycaemic episodes 
observed with insulin detemir in clinical trials could be explained by a difference in:
1. The awareness of symptoms of hypoglycaemia
2. A difference in the slope o f the glucose profiles
3. Whether a difference could be found in EGP and PGU during falling glucose
concentrations.
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Chapter 2
METHODOLOGY 
Trial Population
26 subjects were recruited from the Diabetes Register at The Royal Surrey County Hospital 
with the help of the diabetes specialist nursing team who identified people who might fulfil 
the inclusion criteria and willing to take part. 30 people were approached and 23 agreed to 
take part. Ethics approval for the trial was granted from the East Surrey Ethics Committee. 
The trial was registered on the clinical trials database trial no. NCT00760448 and funded by 
Novo Nordisk A/S. Written informed consent to take part in the study was obtained from all 
the study participants before any trial activities were started, information leaflets were 
provided and the procedures explained..
O f the 26 subjects were screened for inclusion in the study, one subject withdrew consent 
after the first visit before randomisation took place and two were withdrawn for safety 
reasons after difficulty with venous access at the second visit.
Initially 6  subjects were studied at a dose o f 0.4 units/kg for which paired data were obtained 
in 5 subjects. Following this pilot study the dose was increased to try to achieve adequate 
hypoglycaemia and 18 new subjects were dosed at 0.5 units/kg, the original 5 for which 
paired data were obtained were also re studied at this dose.
Inclusion Criteria:
• Age > 18 years o f age
• Type 1 diabetes treated with insulin with duration of diabetes > 12 months.
• Body Mass Index (BMI) of < 30 kg/m2 and HbAic < 10% .
58
Exclusion Criteria:
• Participation in any other clinical trial within three months o f screening
• Hypoglycaemic unawareness or severe autonomic neuropathy
• Treatment with drugs known to interfere with glucose metabolism such as systemic 
corticosteroids, non-selective beta-blockers and monoamine oxidase (MAO) 
inhibitors or treatment with oral antidiabetic drugs.
• Treatment with insulin in a daily dose above 100 U
• An episode of symptomatic hypoglycaemia, or a capillary plasma glucose value
<3.5 mmol/L in the two weeks prior to screening (subjects were counselled to avoid
hypoglycaemia on initial first contact)
• Impaired hepatic function measured as alanine transferase (ALT) > two times the 
upper reference limit
• Impaired renal function measured as creatinine > 150 pmol/L (1.7 mg/dL)
• Cardiac problems defined as decompensated heart failure (New York Heart 
Association (NYHA) class III and IV) at any time and/or angina pectoris and/or 
myocardial infarction within 1 2  months prior to screening.
• Known or suspected allergy to any trial components
• Mental incapacity, unwillingness or language barriers that precluded adequate 
understanding or co-operation
• Any other condition that was felt would interfere with study participation or 
evaluation of results
• Pregnancy or intention of becoming pregnant, breast-feeding or not using adequate 
contraceptive methods. Adequate contraceptive methods were sterilisation, 
intrauterine device (IUD), oral contraceptives or consistent use o f barrier methods
Withdrawal Criteria
A subject would have been withdrawn had following applied:
• Pregnancy or intention of becoming pregnant
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• Withdrawal of consent: subjects had the right to withdraw from the trial at any time 
for any reason. If  the withdrawal had occurred following administration of 
subcutaneous insulin on the study day they were asked to come for a complete post­
trial examination (one subject).
• If  protocol violation or concurrent illness occurred which was judged clinically to 
invalidate the study by interfering pharmacokinetically or pharmacodynamically, the 
subject could have been withdrawn.
• Adverse event: if  a subject reported symptoms which were considered unacceptable 
by the subject or judged to be clinically unacceptable (the appropriate Adverse Event 
record would have been kept and it would have been reported to Novo Nordisk).
Methods and Assessments 
Visit Procedures
Each subject attended four visits at the Centre for Diabetes, Endocrinology and Research 
(CEDAR), The Royal Surrey County Hospital, Guildford, UK. These consisted o f one 
screening visit, two dosing visits (visits 2 and 3) and one follow-up visit (visit 4).
Visit 1 -  Screening Visit
Before screening took place, the subject was provided with written information and the trial 
procedures were explained. Subjects received a screening number in ascending order. 
Screening was performed within 5 to 28 days prior to the date of visit 2 when subcutaneous 
(s.c.) administration of either insulin occurred.
At the screening visit the following was performed and recorded in the notes:
• Signed and dated informed consent
• Inclusion and exclusion criteria
• Demography (date of birth, sex, ethnic origin, smoker/non-smoker)
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• Medical history (including family history, details of illnesses: duration of disease, 
diagnosis and treatment)
• Physical examination
• Weight, height, BMI
• Vital signs
• Standard 12-lead ECG
• Haematology, clinical chemistry, urinalysis, pregnancy test (women of childbearing 
potential), HbAic, fasting C-peptide
• Concomitant medication and medical history
• The subject was asked to perform the cognitive function tests twice in order to reduce 
practice effect on the study day. The results were not recorded.
Physical examination
Physical examination within the following body systems were made at each visit: 
Respiratory system, cardiovascular system, gastro-intestinal system including mouth, 
musculo-skeletal system, central and peripheral nervous system. Any abnormality was 
recorded in the patient’s notes and described in the CRF at Visit 1 and changes in physical 
examination were recorded as adverse events at subsequent visits.
Weight, height and BMI
Weight (without coat and shoes) was measured at Visits 1, 2 and 3. on calibrated 
departmental scales Height (without shoes) was recorded at Visit 1.
Body Mass Index (BMI) was calculated at Visit 1 as follows:
BMI = weight (kg)/ (height (m) x height (m))
The calculated BMI was rounded up/down to nearest whole figure.
All of this data was measured by a single observer (Dr Smeeton)
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Vital signs
Diastolic and systolic blood pressure (after 5 min rest in supine position) and pulse rate 
(after 5 min rest in supine position).
Standard 12-lead ECG
A standard 12-lead ECG was recorded at Visits 1 and 4. The evaluation as normal or 
abnormal without clinical relevance or with clinical relevance was recorded in the notes.
Hypoglycaemic episodes occurring between visits
On attendance to Visits 2, 3 and 4 the subject was asked if he/she had had any 
hypoglycaemic episodes since the last visit.
Hypoglycaemic episodes that occurred between visits were recorded and analysed as 
outlined: date, time of the hypoglycaemic episode, time of last insulin treatment dose prior 
to the episode, type o f last insulin treatment dose prior to the episode, time of last main meal 
prior to the episode, calorie intake in connection to the episode, whether the episode was 
symptomatic, whether the subject was able to treat him/herself, and the plasma glucose 
concentration before treating the episode (if available).
The hypoglycaemia event was considered major if  the subject was not able to treat 
him/herself and required bystander assistance with food, glucagon or i.v. glucose because o f 
severe CNS dysfunction associated with the hypoglycaemic episode (Figure 11). None of 
the subjects had an episode of severe hypoglycaemia meeting these requirements.
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Classification:
< No PG m easure —► Symptoms only orP G ^ 3.1 mmol/lYesHypo- Subject able to
glycaem ic treat the episode^
Episode him/herself? < PG < 3.1 mmol/l ► Minor
No Major
3.1 mmol/L = 56 mg/1
Figure 11: Episodes of Hypoglycaemia: Based on capillary blood glucose calibrated to 
plasma glucose
Hypoglycaemic episodes during the study were only defined as adverse events if  they
fulfilled the definition for a serious adverse event. None of these occurred during the study
period.
Standard Laboratory Safety Assessments
Standard Laboratory safety assessments were performed at Capio diagnostic A.S., Denmark.
Haematology (Visits 1 and 4): haemoglobin (spectrophotometry, ABX protocol, 
Montpellier, France), white blood cell count and platelet count (Impedance, ABX protocol, 
France).
Clinical chemistry (Visits 1 and 4): sodium, potassium (indirect potentiometric procedure 
using an ion selective electrode), creatinine, total protein, albumin, ALT, alkaline
phosphatase (photometry) (all Bayer healthcare, Tarrytown USA).
Urinalysis (Visits 1 and 4): pH, protein, glucose, blood )
HbA}c and C-peptide: HbAlc was measured using HPLC, ion exchange chromatography 
(Abraham 1978) and C peptide using Enzyme Linked Immunoassay (ELISA)
(Dakocytomation, Denmark).
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Pregnancy test: for women o f child-bearing potential only using serum samples for Beta 
Human Chorionic Gonadotrophin (|3HCG) at Visit 1 (Chemiluminescent immunometric 
assay) and urine p HCG samples at Visits 2 and 3 (tested on the study day).
The sampling, storage and shipment procedures were in accordance with the laboratory 
manual and instructions made by Capio Diagnostic A.S.
The first check of the laboratory values were carried out by Capio Diagnostik A.S. Values 
outside the reference range were marked on the laboratory prints and the results of visit 1 
laboratory screens were faxed to the CEDAR Centre. All results outside the reference range 
(clinically significant or not clinically significant) were evaluated, signed and dated. Those 
outside the reference range were non significant apart from in one case where a persistently 
raised alkaline phosphatase in a patient with a past medical history of pancreatitis was 
alerted to his GP for continued monitoring and abdominal ultrasound in the first instance.
Safety Assessments and reporting of adverse events
All results of the clinical investigations mentioned below were recorded and reported to 
Novo Nordisk.
Visits 2 and 3 (study davsk
Once the screening safety visit had been completed and results from the laboratory were 
available, if  the subject fulfilled all o f the inclusion criteria and none of the exclusion criteria 
they were included in the trial. The subject was assigned a subject (randomisation) number.
Subjects attended the Cedar Centre in the evening having fasted from 22:00h before the 
dosing visit to allow an overnight variable infusion of human soluble insulin (actrapid as a 
variable dose insulin infusion). This was done to avoid overnight hypoglycaemia and also 
for safe withdrawal of basal insulin prior to the study day. To avoid any carry-over effect, 
intermediate or long acting insulin, basal insulin was omitted in the 24 hours prior to 
injection of the trial insulin. This necessitated three of the subjects who were normally 
taking premixed insulin twice daily or twice daily insulatard being managed on actrapid with 
meals and omitting their long acting insulin dose the morning before admission. Two o f the
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subjects were using continuous subcutaneous insulin infusion pumps and attended the clinic 
in the morning of the dosing day (visits 2 and 3)
All the subjects had been advised to avoid taking part in strenuous exercise during the 
preceding 48 hours and not to drink alcohol 24 hours prior to attending for the study day due 
to the effects on insulin sensitivity.
To avoid any impact on hypoglycaemia sensitivity, if  subjects had symptomatic 
hypoglycaemic episodes or capillary plasma glucose <3.5 mmol/L at any time in the week 
prior to attending for these visits the visit was re-scheduled.
Cannulation was made with an 18-gauge Venflon cannula inserted into a vein in each arm 
with 2% lignocaine local anaesthesia if  required. One cannula was used for blood sampling 
(this was in a forearm vein that was heated), the other for administration o f various infusâtes 
(human insulin, [6 , 6 -2H2] glucose and 20% dextrose). Saline solution was used to keep the 
blood sampling line patent. For safety 10% dextrose and 20% dextrose solution for 
intravenous administration were available. Hypostop gel and subcutaneous glucagon were 
also available for immediate use.
For the subjects staying overnight, intravenous human insulin infusion was initiated with the 
aim to achieve a stable glucose concentration as close to 7 mmol/L as could be obtained for 
a period of 30 min prior to subcutaneous insulin injection. The infusion rate of human 
insulin was recorded. Subjects remained fasting and in a supine or semisupine position 
during the entire trial day procedure. The subjects were allowed to sip water throughout the 
trial but otherwise had no oral intake.
Most trial procedures started at approximately 06:00h where possible unless there were 
problems stabilising the blood glucose. Time 0 was used to denominate the time that insulin 
was injected subcutaneously.
At time -160 min (06:20) a bolus of 170 mg [6 , 6 -2H2] glucose was injected over one min 
followed by a constant infusion of 1.7 mg/min [6 , 6 -2H2] glucose which continued for the 
rest o f the study. A baseline blood sample for blood and plasma glucose was taken before
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the infusion o f the isotope was initiated to measure basal glucose enrichment. An 
equilibrium period was allowed for tracer enrichment to reach steady state before taking 
steady state samples at -40 min to -10 min.
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From -40 min and until immediately before insulin administration subcutaneously (0 min), 
samples were drawn for assessment of baseline levels of counter-regulatory hormones 
(adrenaline, noradrenaline, glucagon, cortisol, growth hormone and insulin-like growth 
factor binding protein 1 (IGFBP1), NEFA, human insulin, blood and plasma glucose as well 
as enriched glucose according to the blood sampling scheme below (tables 2 & 3). Cognitive 
function tests were performed three times before the trial insulin was injected and heart rate 
and blood pressure were also recorded four times (Figure 12).
Insulin Administration
Before setting the dose, the NPH insulin penfill® was adequately tipped in order to obtain 
complete resuspension. Thereafter, for both insulin detemir and NPH insulin, an air shot of 
2 0  units was made with the needle turning upwards, followed by another tipping of the 
cartridge, and a final air shot o f 2 0  units with the needle turning upwards.
The dose setting and administration followed general procedures for insulin preparations:
• Insulin detemir: one click on the Novopen® equals one unit (equal to 24 nmol) of insulin 
detemir.
• NPH insulin: one click on the Novopen® equals one international unit (equal to 6  nmol) 
o f human insulin.
For both insulin preparations the volume expelled was 10 pl/click and the number o f clicks 
on the Novopen® was calculated as: Dose (U/kg) x body weight (kg). The body weight at 
Visit 1 was used for dose calculation.
At time 0 min when the plasma glucose concentration was maintained (aiming for 7 mmol/L 
for 30 min) the insulin was administered subcutaneously in the thigh by a qualified person 
not otherwise involved in the trial. This was necessary to “blind” the study because insulin 
detemir is clear and NPH insulin cloudy, therefore a clear visual clue would be visible to the 
subject and trialist. This was prescribed on a hospital drug chart.
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The protocol was divided into three sections following insulin injection s.c.:
Scheme 1: Blood glucose at the start until blood glucose had fallen to 4 mmol/l,
Scheme 2: Blood glucose falling from 4 to 2.4 mmol/l or at such time that the subject could 
not tolerate hypoglycaemia, or after 8  hours from insulin administration s.c.
Scheme 3: The rescue period when 20% dextrose was infused at 6 mg/kg bringing the blood 
glucose to 6  mmol/l.
The target glucose level was 2.4 mmol/l. If  this value was not reached the study was stopped 
at the time limit o f eight hours or a time at which the subject could not tolerate the 
symptoms of hypoglycaemia. Once the rescue infusion o f 20% dextrose had brought blood 
glucose up to 6  mmol/l, food and drink were given.
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Table 2: Blood Sampling Scheme (Visits 2 and 3)
Approximate
hour
Nominal
Times
s/e insulin injection and 
infusions
Insulin detemir 
/human insulin
Enriched glucose 
[6,6-2H2-glucose]
Day -1
Start o f  i.v. human insulin 
infusion
6.20 -160 min
Start o f  primed cont. 
[6,6-2H2]glucose infusion
X X
08.20 -40 min X
08.30 -30 min X X
08.40 - 20 min X X
08.50 - 10 min
Tapering o ff  i.v. human 
insulin infusion
X X
09.00 0 min s/e insulin administration X X
10.00 1 hour X
Every 20 min
11.00 2 hours X
12.00 3 hours X
13.00 4 hours X
14.00 5 hours X
15.00 6 hours X
16.00 7 hours X
17.00 8 hours X
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Table 3: Visits 2 and 3 scheme 1 ,2  and 3 blood sampling times (T=time)
Scheme 1 Scheme 2 Scheme 3
BG=; 1 Gd
_ 
Î mM BG=2.4 mM BG=4 mM BG=6
1
Plasma glucose
T = -40, -30, -20, -10, 0 
min
20 min 
intervals
5 - 1 0  min 
intervals
5 - 1 0  min 
intervals
5 - 1 0  min 
intervals
PD samples 
(counter­
regulatory 
hormones)
T = -40, -20, 0 min Hourly
20 min 
intervals
T = 0, 10, 30, 60 min
Cognitive 
function tests
T = -60, -30, -15 min Hourly
15 min 
intervals
15 min 
intervals
15 min 
intervals
Hypoglycaemia
symptoms
questionnaire
T - -180 min Hourly
15 min 
intervals
15 min 
intervals
15 min 
intervals
Heart rate and 
blood pressure
T = -180, -60, -30, 0 
min
30 min 
intervals
15 min 
intervals
15 min 
intervals
15 min 
intervals
S/c insulin Glucose administration
administration, T=0
Scheme 1 : From nominal time -180 min until blood glucose dropped to 4 mmol/L 
Scheme 2: From blood glucose 4 mmol/L until blood glucose had dropped to 2.4 mmol/L.
Scheme 3: From blood glucose is 2.4 mmol/L until blood glucose had increased to 6 mmol/L.
Autonomic Response
Heart rate was recorded at -180, -60, -30 and 0 min. Thereafter it was recorded every 30 min 
until blood glucose had dropped to 4 mmol/L and then every 15 min throughout the 
experiment.
Systolic and diastolic blood pressures were recorded at the same time-points as heart rate. 
The time-point when the heart rate was 15% above average baseline was calculated.
71
Hypoglycaemia Symptoms Questionnaire
A hypoglycaemia symptoms questionnaire (Appendix 1) based on the Edinburgh 
Hypoglycaemia Scale was completed (Deary et al 1993, McAuley et al 2001) with a linear 
interval scale for each symptom recorded. The scale ranks each symptom from 1 (not at all) 
to 7 (a great deal). The scores for autonomic symptoms, neuroglycopenic symptoms and 
general malaise were made:
• Autonomic symptoms: sweating, palpitations, shaking, hunger
• Neuroglycopenic symptoms: confusion, drowsiness, odd behaviour, speech difficulty,
incoordination
• General malaise: headache, nausea
Subjects were asked to complete the questionnaire at baseline (-180 min) and thereafter 
hourly from trial product administration until plasma glucose had reached 4 mmol/L. 
Thereafter, the questionnaire was completed every 15 min throughout the experiment (table 
3). There were 11 symptoms recorded at each stage and the symptom score was later 
recorded according to the change from the baseline score e.g. hunger was often scored at the 
start as well as when symptomatic from hypoglycaemia. These were then summed for each 
category and overall.
Cognitive Function Tests
Finger Tapping Test: A computer key was pressed as many times as possible for 
10 seconds. The test was repeated three times at each defined time-point and the mean score 
calculated (Bingham et al 2003).
Four Choice Reaction Time Test: A computer screen randomly displayed a dot in one of 
four possible fields. The subject responded by pressing the corresponding positioned key on 
a keypad. Each test was carried out with 100 cycles. Number correct (out o f 100), mean 
correct time (msec) and standard deviation for correct time (msec) were recorded 
(Wilkinson and Houghton 1975).
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The cognitive function tests were performed at baseline and then hourly after subcutaneous 
insulin administration until blood glucose concentration reached 4 mmol/L. Below this point 
the tests were performed every 15 min throughout the experiment (table 3).
Visit 4 - Follow-up Visit
Subjects attended the CEDAR centre for a follow-up visit within 28 days following Visit 3. 
The following were checked:
• Physical examination (if changes compared to Visit 1 were observed, an Adverse Event 
Form was filled in for reporting to Novo Nordisk)
• Vital signs
• 12-lead ECG
• Haematology, clinical chemistry and urinalysis
• Adverse events
• Concomitant medication
• Hypoglycaemic episodes since the last visit
Trial Materials
• Insulin detemir 100 U/mL (2400 nmol/mL) in 3.0 mL Penfill
• NPH insulin (Protaphan) 100 lU/mL (600 nmol/mL) in 3.0 mL Penfill
Actrapid 100 lU/mL in 3.0 mL Penfill and isotonic sodium chloride for dilution. Novo 
Nordisk A/S, Denmark, provided the trial products.
Packaging and Labelling o f Products
A box containing one insulin detemir Penfill and one NPH insulin Penfill were provided for 
each subject. In this box each Penfill was placed in a separate box labelled with subject 
number and visit number by pharmacy according to prescription.
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In total 22 boxes were provided for subjects 01 to 22. Another 22 boxes were provided for 
replacement subjects (numbers 101 to 122). Replacement subjects were allocated to the 
same trial product sequence as the subjects he/she replaced using the corresponding number 
(101 to 122). A further supply was required due to withdrawals after pharmacy had 
dispensed some of the insulin. These were returned to pharmacy.
Actrapid (human soluble insulin) was provided for the human insulin infusion. 50 units were 
diluted in 50 mis of normal saline (0.9%) to a concentration of one unit per ml and infused 
according to the blood glucose. Trial products and infusions were labelled.
Storage and Drug Accountability o f Products
Trial products were not dispensed to any person not enrolled in the trial. Accurate records of 
all trial products received and the products used for each subject were kept. Insulin detemir, 
NPH insulin (Protaphan/Insulatard), and human soluble insulin (Actrapid) were stored 
refrigerated (2 to 8 °C) in Pharmacy. Used and unused cartridges were stored separately.
Randomisation and Blinding
The trial was double-blind with insulin preparation sequences allocated according to the 
randomisation. When a subject was randomised in the trial, he/she was assigned to the 
lowest available randomisation (subject) number. Subjects were allocated subject numbers 
from 01 to 23. Replacement subjects were allocated to the same trial product sequence as the 
subject he/she replaced using corresponding subject numbers from 101 to 123 (subjects 
1,2,3,4,5 were re studies as 101,102,103,104,105).
Three sets of sealed codes with the randomisation number containing information about the 
insulin preparation for the particular subject at each visit were prepared for each subject. 
One set was kept at the trial site in pharmacy (during the entire trial period), one set was 
kept by Novo Nordisk Ltd, UK, and one set was kept by International Product Safety, Novo 
Nordisk, Denmark.
A copy of the randomisation list was sent to the responsible person at Capio Diagnostik a.s. 
The randomisation was kept blinded for all other persons involved in the trial.
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Breaking of Blinded Codes
The code for a particular subject could have been broken in a medical emergency if knowing 
the identity of the insulin preparation allocation would influence the treatment o f the subject. 
None of the codes were broken during the trial.
All codes were kept throughout the trial period.
Blood Samples
Blood samples for analysis o f insulin detemir/human insulin, adrenaline, noradrenaline and 
glucagon were handled according to the description in the laboratory manual supplied by 
Capio Diagnostik A.S. and were performed by Capio Diagnostik A.S. (after shipping on dry 
ice).
The blood samples drawn for total (unlabelled) and enriched glucose, cortisol, growth 
hormone (GH), IGFBP-1 and NEFA, were treated according to local laboratory procedures 
as detailed below and analysed at the Wolfson Centre for Translational Research, 
Postgraduate Medical School, University of Surrey by Dr Nicola Jackson and Dr Fariba 
Shojaee-Moradie.
Blood samples were separated immediately and stored at -20°C until assayed. Adrenaline, 
noradrenaline and glucose were put in an ice bath, separated within 1 0  minutes and then 
stored at -40°C before shipping in dry ice to Capio Diagnostik A.S.
Insulin
Serum insulin detemir concentrations were analysed using an insulin detemir specific 
ELISA assay (Heinemann et al 1999).
Serum human insulin concentration (after administration of NPH insulin only) was analysed 
using the DAKO insulin ELISA assay. The intra-assay CV was 5.1-7.5% and the inter-assay 
CV was 4.2-9.3%.
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Adrenaline and Noradrenaline
Adrenaline, noradrenaline were analysed using HPLC after extraction (chromosystems, 
Munich, Germany). The intra-assay CV was 1.7-11.4% and the inter-assay CV 3.7-12.7%.
Glucagon
This was assayed at Capio Diagnostik by Radioimmunoassay technique. (Diagnostic 
products corporation, USA). The intra-assay CV was 4-6.8% and the inter-assay CV 7.3- 
13.5%.
Cortisol
Cortisol was measured by a solid phase ELISA (DRG international Inc, NJ, USA) based on 
the principle of competitive binding. Microtitre wells were coated with a monoclonal 
antibody directed towards a unique antigenic site on the cortisol molecule. Endogenous 
cortisol of the patient competed with a cortisol horseradish peroxidase conjugated for 
binding to the coated antibody. After incubation the unbound conjugate was washed off. The 
amount of bound peroxidase was reversely proportional to the concentration o f cortisol in 
the sample. After addition of the substrate solution the intensity of colour development 
measured by absorbance was reversely proportional to the concentration of cortisol in the 
patient sample.
The within assay variability for 20 samples each was a CV of between 3.2% and 8.1% and 
the intra assay variability a CV of between 6.5 and 7.7%.
Growth Hormone (GH)
GH was analysed using a serum coated bead immunoradiometric assay (IRMA) (Skybio 
Ltd, Wyboston, Bedfordshire, UK). Buffer solution was diluted to 1:99 with distilled water. 
Tracer 1 2 5 1-anti GH was reconstituted with 1ml of de ionised water then when ready to use 
diluted in assay buffer 1:99. The count rate o f this solution should be between 40,000 and 
60,000 counts per minute. The coated beads were allowed to warm to room temperature.
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Standards and QC’s were performed and tests performed in duplicate. 200 pi of tracer 
solution 125I anti-GH was added to each tube and total count tubes were prepared by adding 
2 0 0  pi to the tubes.
One anti GH coated bead was added to all tubes except total counts followed by vortexing 
then mixing for 16 hours using a rotating tube holder. The next day 2ml wash solution was 
added to all except the total counts tubes. Each o f the tubes were washed twice more before 
the bound radioactivity was counted for 60 seconds using a gamma counter (Wallac Wizard 
1470, UK).
A graph o f % (bound/total) count vs. log GH concentration for the standards and 
concentrations of the QC’s and unknown test results were performed automatically using a 
data reduction software package using Ria Calc software (Wallac/Pharmacia).
The intra assay CV was between 2-3% and the inter assay CV of 5-6%.
IGFBP1
IGFBP1 was measured by IRMA (coated tube-immunoradiometric assay kit DSL-7800) for 
total IGFBP-1. The tracer was an 125I-labelled antibody to IGFBP1. This is the same 
principle as the growth hormone assay with the exception that the first antibody was coated 
onto the tube. The antigen (IGFBP-1) was sandwiched between coated antibody and labelled 
antibody, the more radioactivity left in the tube, the more antigen in the sample. The sample 
was read off from a standard curve which was measured in each assay. The intra assay CV 
was 2.7-5.2% and inter assay CV 2.3-6%.
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NEFA
NEFA was measured using a RANDOX Laboratories Ltd Colorimetric Kit (Randox 
Laboratories, Co Antrim, Northern Ireland) on an automated analyser (MIRA analyser, 
ABX diagnostics, Montpellier, France). The principle is as follows:
NEFA + ATP +CoA AcetylCoA synthetase Acyl CoA + AMP + Ppi 
Acyl CoA + 0 2AcylCoAQxidase» 2, 3,-Trans-Enoyl-CoA + H2O2 
2 H2O2 + TOOS +4-AAP Peroxidas£ purple adduct+4 H20  
Where 4-AAP = 4-aminoantipyrine and 
TOOS = N-ethyl-N-(2hydroxy-3-sulphopropyl) m-toluidine 
Normal range 0.1-0.9 mmol/1
The inter-assay CV was 6 %.
Glucose Concentration
Blood glucose concentration was monitored initially at 20 min intervals until blood glucose 
had fallen below 4 mmol/ when this increased to 5 to 10 min intervals. Plasma glucose and 
glucose enrichment samples were taken every 20 min throughout. Sample tubes for glucose 
contained fluoride oxalate. Blood and plasma glucose were measured using a glucose 
oxidase technique on a glucose analyser (YSI 2300 Clandon Scientific, Yellow Springs 
Instruments, Yellow Springs, Ohio, USA). This method is based on glucose oxidation. 25 
pi of blood or plasma was aspirated by a sipper, which then transferred and injected the 
sample into a buffer filled sample chamber. Some of the substrate diffuses through a 
membrane where it contacts the immobilized oxidase enzyme; it is rapidly oxidised 
producing hydrogen peroxide (reaction 1 )
Reaction 1
p-D-glucose + O2 glucose oxidase k Glucono-5-lactone + H2O2
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The hydrogen peroxide (H2O2) is in turn oxidised at the platinum anode producing electrons 
(reaction 2)
Reaction 2
H2O2 2H+ + O2 + 2 e"
A dynamic equilibrium is achieved when the rate of H2O2 production and the rate at which 
H2O2 leaves the immobilised enzyme layer are constant and is indicated by a steady state 
response. The electron flow is linearly proportional to the steady state concentration and 
therefore the concentration of glucose. The platinum electrode is held at anionic potential 
and is capable of oxidising many substances other than H2O2 . To prevent these reducing 
agents from contributing to the sensor current the membrane contains an inner layer 
consisting of a very thin film o f cellulose acetate. The film readily passes H2O2 but excludes 
chemical compounds with molecular weights above approximately 200. The analyser was 
calibrated before use using glucose standard solution 25mmol/l, and standard normal and 
“pathological” solutions with glucose concentrations of 2.5 mmol/1 and 13 mmol/1 
respectively.
Glucose Enrichment:
Analysis of [6 , 6 -2H2]glucose (enriched glucose) was performed at The Department of 
Diabetes and Endocrinology, St Thomas Hospital and the Wolfson Centre for Translational 
Research, Postgraduate Medical School, University of Surrey.
The isotopic enrichment of plasma glucose was determined as the trimethylsilyl O- 
methyloxime derivative (methoxy-TMS): a method previously employed by Laine and 
Sweeney (1971) by gas chromatography mass spectrometry (GCMS) on a HP 5971A mass 
selective detector (Agilent Technologies, Berkshire, U.K.). After centrifugation at 4°C, 2500 
rpm for 10 minutes, the samples were deproteinised by the addition of 0.5ml of ethanol and 
repeat centrifugation for 10 minutes at the same settings as before. The supernatant was 
then removed and dried under a continuous stream of OFN (oxygen free nitrogen) at 50°C.
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The sample was then treated with lOOjal of methylhydroxamine hydrochloride (freshly made 
in pyridine 2% w/v). Following this, the solution was then heated at 90°C for 2 hours. Once 
cooled, 5 0 jli1 BSTFA (N, O-Bis (trimethylsilyl) trifluoroacetamide with 
trimethylchlorosilane) was added, followed by additional heating at 120°C for 15 minutes.
Excess reagents were removed under OFN at room temperature and then the sample was 
reconstituted in 5 0 0 jli1 of decane. 50pl o f the above sample was further diluted in 500pl of 
decane. Samples were injected (Ipl) by the auto sampler in the splitless mode. The injection 
port temperature was 250°C. The GC column (30m, 0.25mm ID, 0.25pm df, 100% 
dimethyl polysiloxane) temperature was held at 120°C for 1 min and then increased at 
20°C/minute to 300°C and held at the final temperature for 1 min. The total run time was 12 
min. The MS was operated in the positive ion El mode (70eV). The ions monitored were at 
m/z 319 (m+0) and 321 (m+2) using a dwell time of 25 msec, giving 11.76 cycles/sec. A 
typical ion chromatograph of m/z 319 and 321 from a plasma sample are shown in figure 13:
80
Abundance 
60000 -
Ion 319.00 (318.70 to 319.70): 1101006.D
40000
20000
Time— > 7.60 
Abundance
60000 -
7 . 6 5 7.70 7.75 7.80 7.85 7.90
Ion 321.00 (320.70 to 321.70): 1101006.D
40000 -
20000  -
Time— > 7.60 7.70 7.757.65 7.857.80 7.90
Figure 13: Typical ion chromatographs showing m/z 319 and m/z 321 in a plasma 
sample
Sample Size Calculation
The primary objective of this trial was to compare symptoms o f hypoglycaemia after single 
doses of insulin detemir and NPH insulin in subjects with type 1 diabetes. The primary 
endpoint was defined as the baseline-adjusted hypoglycaemia symptoms score at nadir 
plasma glucose concentration.
The sample size was determined as the number of subjects needed in the trial in order to 
detect a clinically relevant difference in the primary endpoint with regard to insulin 
preparation.
In an earlier cross-over trial investigating insulin aspart where hypoglycaemia was induced 
by intravenous infusion of insulin aspart or human soluble insulin (Frier et al 2000), the 
standard deviation of within-subject difference in hypoglycaemia symptoms score at onset 
of the autonomic response were estimated to be 13.7, and thus in the following power 
calculation the rounded value of 14 was used as the standard deviation.
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The table below shows the power to detect certain absolute within-subject differences in 
hypoglycaemic symptoms score between insulin detemir and NPH insulin for various 
numbers of subjects treated. The power was calculated using a two-sided paired t-test and a 
significance level of 5%.
Table 4: Power calculation
Absolute Difference Number of Subjects
(Effect Size) 10 14 18 22 26
7
(0.5)
29% 41% 51% 60% 68%
8.5
(0.6)
40% 55% 68% 77% 84%
10
(0.7)
52% 69% 81% 89% 93%
14
(0.8)
80% 93% 97% 99% 99%
When aiming at a power above 80%, between 18 and 22 subjects would be sufficient to 
detect a within-subject difference in hypoglycaemia symptoms score of 10 (corresponding to 
an effect size o f 0.7). In order to allow for possible drop-outs, 22 subjects were planned to 
be randomised. Novo Nordisk provided help with this power calculation.
Data analysis
Glucose Metabolism
The glucose profiles were plotted against time from injection and also as time from blood 
glucose nadir. When plotted against time from injection the mean o f the values were 
calculated according to the time at which they occurred. When plotted against blood glucose 
nadir, the time and value o f the nadir was identified as zero and the time of each 
measurement calculated as the time o f the measurement minus the time of the nadir.
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Baseline blood glucose was the average concentration in the 30 min before insulin injection. 
To derive endpoints interpolated 5-min intervals were used. The slope o f the blood glucose 
profile was determined as the slope of the blood glucose concentration curve at nadir using 
the two blood glucose concentration values recorded immediately before nadir and the value 
at nadir. The slope o f the blood glucose concentration before the onset of the autonomic 
response which was defined as the acute rise in heart rate to 15% above baseline.
Endogenous glucose production rate (EGP) and Peripheral glucose uptake (PGU) were 
calculated using Steele’s non-steady state equations (Steele 1956) modified for stable 
isotopes. Before calculation of glucose turnover, plasma glucose concentration and glucose 
enrichment time courses were smoothed and interpolated to 5 minute intervals using optical 
segments technique analysis (Finegood 1888).
The Steele Equation
EGP = F-nV rtC? +Ci V21 (fTTRo-TTRiV fW ,)l 
TTR2-TTR1
PGU = EGP -pV  (C2-Ci)/(t2-ti)
Where F= infusion rate (mg/min) corrected for % enrichment 
P= fraction of plasma pool (0.65)
V= total extracellular glucose pool (calculated as 0.221/kg body weight)
TTR= tracer/tracee ratio 
t=time (mins)
The numbers 1 and 2 refer to adjacent sampling times (mins)
C=glucose concentration (mg/1)
The glucose concentration and the TTR of the enriched 20% glucose infusâtes and the 
glucose concentrations of the tracer infusate were all measured and these values used in the 
calculations.
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For each time point EGP and PGU were calculated. For each subject in each study the mean 
glucose EGP and PGU at a glucose concentration of 7.0, 6.5, 6.0, 5.5, 5.0, 4.5, 4.0, 3.5, 3.0 
and 2.5 mmol/1 were calculated. The boundaries for each concentration were +/- 0.05 
mmol/1, so for example, any concentration between 5.95-6.05 mmol/1 was considered to be a 
concentration of 6mmol/l. For some concentrations there was only 1 value for others there 
were 3 values.
Hypoglycaemia symptom score
The analysis compared symptoms of hypoglycaemia after single doses o f insulin detemir 
and NPH insulin in subjects with type 1 diabetes. The HSS (hypoglycaemia symptoms 
score) mean profile was plotted as a function of time since trial drug injection and time since 
glucose nadir. The total HSS was derived as the mean score for the 11 different symptoms 
multiplied by 11. The baseline HSS was calculated as the average total HSS assessed before 
trial drug injection. The nadir HSS was calculated as the total HSS assessed at the time (or 
as close as possible) when the minimum blood glucose concentration was measured. In 
those cases where minimum blood glucose concentration was obtained at more than one 
time-point, the mean score for all time-points in question was used.
The nadir HSS minus the baseline HSS which was calculated could in theory take values - 
66, -65, 66, where positive values indicate more severe symptoms compared with baseline.
A change in baseline-adjusted HSS was defined as the first time-point where baseline- 
adjusted HSS was increased by at least 15% compared to the average baseline-adjusted HSS 
assessed at the two previous time-points.
Autonomic response
This was measured as the heart rate and blood pressure when the glucose concentration was
2.4 mmol/1 for the first time.
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Cognitive function
The mean number o f taps in 10 seconds were recorded, a change in the finger tapping was 
defined a change o f 15% from baseline. A change in 4 choice accuracy or a change in four 
choice time was defined as the first time point when a decrease of 15% occurred when 
compared to the mean before injection.
Insulin concentrations
These end points were derived from the individual profiles of human insulin and insulin 
detemir, area under the curve was calculated using the trapezoidal technique.
Counterregulatory hormones
For all of the counterregulatory hormones (adrenaline, noradrenaline, glucagon, cortisol, 
growth hormone and IGFBP1) the concentration at baseline was calculated as the mean of 
the 3 baseline values, Cmax was the baseline adjusted maximum concentration and T max 
was the time to peak concentration.
NEFA response was determined by the area over the curve from baseline to time of onset of 
autonomic response and was the difference between two areas: the area of the rectangle with 
0 min to time of autonomic response as one side and NEFA at baseline minus the area under 
the NEFA curve calculated using the trapezoidal technique as the other. Only values above 
the line were used, i.e. no negative values were included.
Statistical analysis
The mean EGP and PGU at each glucose concentrations in the insulin detemir study and in 
the NPH study were then calculated and each series compared using a one way ANOVA 
(analysis of variance). Baseline EGP and PGU were calculated as a mean of the EGP and 
PGU values at time 0 before injection.
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A test for no difference in symptoms of hypoglycaemia between insulin detemir and NPH 
insulin was carried out using an ANOVA model with insulin preparation, dose level, 
interaction between insulin preparation and dose level and visit as fixed effects, subject as a 
random effect and an error term with a variance depending on insulin preparation. 
Subsequently, the model was reduced by removing the visit effect and the interaction 
between insulin preparation and dose, because the p-values for these effects were non­
significant.
For both the insulin concentration and counterregulatory hormones (including NEFA) Cmax 
was determined as the maximum of all valid concentration measurements for each 
measurement series and Tmax was determined as the corresponding time-point. The area 
under curve (AUC) in the stated time-frame was derived using the trapezoidal technique.
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CHAPTER 3
RESULTS
Subject Characteristics
O f the first eight subjects recruited, five completed both study days successfully and were 
dosed at 0.4 Unit/kg o f subcutaneous insulin. One subject managed one study day but was 
unable to complete the second due to difficulty with venous access, one subject was also 
difficult to cannulate and became distressed therefore was withdrawn and a further subject 
was withdrawn after symptomatic hypoglycaemia occurred just after the subcutaneous 
insulin was administered i.e. due to the persisting metabolic effects of the overnight insulin 
and not the trial insulin.
After these five subjects had completed both visits the blinded data was reviewed and as 
hypoglycaemia had not been adequately achieved on both visits subsequent studies were 
carried out at a dose of 0.5 Units/kg. 19 subjects were planned to be studied at this dose, this 
included the original five re-entered in the study. One of the 19 subjects withdrew consent 
after screening. Four of the remaining 18 failed to reach adequate hypoglycaemia on both 
visits and were excluded from the analysis before the study was unblinded. This left 14 
subjects, the data from whom are presented in the final statistical analysis.
The results presented here are for 14 subjects who completed both studies and achieved 
hypoglycaemia (11 male, 3 female; age 31 ± 8.2 years; BMI 24.8 ± 1.97 kg/m2; weight 77 ±
9.4 kg; duration of diabetes 13± 9.8 years; HbAlc 7.8 ± 0.71% (mean ± SD) (Table 5). This 
data was distributed normally.
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Table 5: Subject characteristics
Subject Gender Age
(years)
Weight
(kg)
BMI
(kg/m2)
H bA lc (%) Duration o f
Diabetes
(years)
Total daily 
dose o f  
insulin (IU)
1 M 45 87.5 28.6 6.9 7 44
2 F 42 49.5 22.0 7.0 31 20
3 M 22 83.5 22.9 6.7 5 71
4 M 20 72.0 25.5 8.8 7 64
5 F 31 74.8 25.0 7.9 27 44
6 M 36 79.9 25.2 7.9 2 42
7 M 32 84.0 26.5 8.3 21 58
8 M 27 73.0 22.3 8.6 36 50
9 M 34 85.0 26.2 7.5 18 42
10 M 31 80.1 27.6 7.3 36 52
11 M 31 73.9 25.0 8.0 7 67
12 M 29 78.3 25.6 8.3 3 30
13 F 20 81.8 29.0 8.8 2 45
14 M 29 72.0 24.9 6.9 22 55
Blood Glucose Concentrations
Following administration of insulin detemir or NPH insulin the blood glucose concentration 
decreased from baseline values o f 7.0 ±1.1 (mean ± SD) and 7.3 ± 1 .2  mmol/1 respectively 
to 2.6 ± 0.5 and 2.8 ± 0.6 mmol/1 at blood glucose nadir (Figure 14; table 6). There were no 
relevant differences in endpoints related to blood glucose profiles, either time for blood
glucose nadir or nadir blood glucose (p=0.699). There was also no difference in the slope of 
the blood glucose profiles.
In figure 15 blood glucose concentration is plotted against time from blood glucose nadir 
because each subject’s blood glucose concentration declined to blood glucose nadir at a 
different rate and also to a different concentration. The blood glucose nadir was set at time 
zero and the time of each measurement calculated as the time of the measurement minus the 
time of the nadir. After the administration of NPH seven out of the 14 patients achieved 
target hypoglycaemia and 3 patients stopped due to intolerable symptoms o f hypoglycaemia 
whereas with insulin detemir 9 o f the 14 patients achieved target hypoglycaemia and 5 
patients terminated early due to intolerable symptoms.
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Table 6: Nadir time and nadir blood glucose concentration for each subject
Subject Nadir 
time NPH  
(min)
Nadir
blood
glucose
NPH
(mmol/1)
Nadir time
detemir
(min)
Nadir Blood 
Glucose 
detemir 
(mmol/1)
1 480 2.7 365 2.0
2 420 2.4 270 2.0
3 355 2.4 280 2.3
4 480 2.6 440 2.0
5 290 2.3 270 2.1
6 380 3.1 390 3.0
7 310 3.4 330 3.3
8 250 2.3 180 2.4
9 260 2.2 400 2.4
10 270 2.4 300 2.0
11 285 2.8 370 2.8
12 480 4.1 290 3.2
13 480 3.8 430 3.0
14 290 2.2 390 2.4
Mean ±  SEM 359 ±25 2.8 ± 0 .6 336 ± 2 0 2.6 ± 0 .5
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Figure 14: Blood glucose concentration from baseline time 0 = time of s/e injection 
(mean ± SEM)
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Figure 15: Blood glucose concentration plotted as time from the blood glucose nadir 
(mean ± SEM).
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Plasma Glucose
Samples were taken every 20 minutes throughout both studies for the measurement of 
plasma glucose and plasma enrichment with 2H2 glucose. EGP and PGU were calculated 
from these samples. During the study blood glucose and plasma glucose concentrations were 
measured. In the original study design a plasma glucose level of 2.4 mmol/L was the target 
level where Hypostop or i.v. glucose was to be given however blood glucose concentration 
was used to determine the nadir by mistake in the first 5 subjects. At a blood glucose 
concentration between 2 and 5 mmol/L, plasma glucose concentration is between 0.2 and 
0.6 mmol/L higher than blood glucose concentration. The implication is that in some 
subjects, the study was terminated earlier than planned in the original design. However as 
many subjects did not reach a blood glucose (or plasma glucose) level of 2.4 mmol/1 this did 
not significantly impact on the results (Figure 16).
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Figure 16: Plasma glucose concentration plotted as time from nadir (mean ± SEM)
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Glucose Metabolism
At baseline (pre study insulin injection, when all subjects were on intravenous soluble 
human insulin) there were no significant differences in either glucose EGP or PGU. A one 
way ANOVA was applied to glucose concentrations from 3.5mmol/l to 2.5mmol/l.
EGP and PGU were plotted against glucose concentration so that direct comparison could be 
made between the two insulins at a given level of blood glucose. This was chosen because 
there was a great deal of variability in the end point time between subjects and between 
insulin preparations. After injection of insulin EGP was observed to be consistently lower 
with insulin detemir when compared to NPH insulin at the same glucose concentration 
suggesting that insulin detemir exerted a greater suppressive effect on EGP (p=0.001) 
(Figures 17 and 18). Similarly PGU was observed to be consistently lower with insulin 
detemir when compared to NPH insulin at the same glucose concentration suggesting that 
insulin detemir exerted a lesser effect on PGU (p=0.005) (Figures 19 and 20 ).
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Figure 17: EGP plotted against time from injection (mean ± SEM)
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Figure 18: EGP plotted against plasma glucose concentration (mean ± SEM)
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Figure 19: PGU plotted against time from injection (mean ±  SEM)
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Figure 20: PGU plotted against plasma glucose concentration (mean ± SEM)
The number of subjects with a measured EGP and PGU at each glucose concentration is 
shown in table 7.
Table 7: number of observations in each group, EGP and PGU
Plasma glucose
concentration
(mmol/l)
Insulin detemir 
EGP n=
NPH insulin 
EGP n=
Insulin detemir 
PGU n=
NPH insulin 
PGU n=
6 13 13 12 12
5.5 13 13 13 13
5 14 14 14 14
4.5 14 14 14 14
4 14 13 14 14
3.5 13 11 13 11
3 10 11 9 11
2.5 7 4 6 4
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The number o f observations is generally lower at the higher glucose concentration values 
due to the differing rate of fall and variable starting glucose concentration. The number of 
observations diminishes with declining glucose concentration due to the different end point 
values.
Hypoglycaemia symptoms
A modest increase in HSS was seen during development of hypoglycaemia (table 7). A test 
for no difference in symptoms of hypoglycaemia between insulin detemir and NPH insulin 
was carried out using an ANOVA model as described in the methods. The baseline adjusted 
HSS at nadir blood glucose did not differ significantly between insulin detemir and NPH 
insulin (estimated difference -1.01; 95% Cl [-9.55; 7.54]; p=0.758). No relevant differences 
between insulin detemir and NPH insulin were observed in hypoglycaemic awareness 
endpoints.
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Table 8: Hypoglycaemia Symptom Score Results (HSS)
Insulin HSS at 
baseline (0 
min)
Baseline 
adjusted 
hypo score at 
nadir blood 
glucose 
(mmol/l)
Time when a 
change in 
hypo score 
occurs (min)
Blood 
glucose 
(mmol/l) 
associated 
with change 
in hypo score
Detemir N 14 14 14 14
Mean 13 9 172 5.3
Median 12 5 120 4.9
SD 1.6 11.8 125 1.8
Minimum 11 2 60 2.9
Maximum 17 35 420 4.1
NPH N 14 14 13 13
Mean 13 10 179 5.6
Median 12 6 180 5.5
SD 1.3 12.4 57 2.0
Minimum 11 -4 60 2.7
Maximum 15 39 360 4.5
Cognitive Function
There was no statistical difference in the cognitive function test results between insulin 
detemir and NPH. There was little change in most subjects finger tapping or cognitive 
function from baseline therefore the numbers were very small with no consistent pattern
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observed (only 2 subjects showed a change in finger tapping and 4 choice reaction time and 
this was not in hypoglycaemia). As the rate o f decline in blood glucose was different for 
each subject the results in table 9 are shown according to 1 mmol blood glucose increments. 
For example a blood glucose o f 3.0 mmol/l corresponding to mean values obtained in mean 
4 choice reaction time (4CRT) between a blood glucose of 2.5-3.49 mmol/l and that of 4.0 
mmol/l representing 3.5-4.49 mmol/l and so on.
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Table 9: Cognitive Function Test Results
Insulin Time when a 
change in 
FTT 
occurred 
(min)
Blood 
glucose at a 
change in 
FTT 
(mmol/1)
Time when a 
change in 
4CRT 
occurred 
(min)
Blood
glucose at a 
change in 
4CRT 
(mmol/1)
Detemir N 2 2 3 3
Mean 180 5 332 5
Median 180 5 305 4
SD 0 0 108 2
Minimum 180 4 240 3
Maximum 180 5 450 7
NPH N 2 2 4 4
Mean 250 5 320 4
Median 250 5 363 3
SD 99 0 144 1
Minimum 180 4 120 3
Maximum 320 5 435 5
Autonomic Function
No difference was observed between the two insulins in the time of onset o f autonomic 
response (a rise in pulse rate of 15% above baseline) (p=0.907) and no observed difference
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in the pulse for those that reached the target blood glucose of 2.4 mmol/1. (p=NS). Only 9 
subjects dosed with insulin detemir and 7 of those dosed with NPH achieved the target blood 
glucose o f 2.4 and 11 subjects dosed with insulin detemir and 10 dosed with NPH had an 
autonomic response as defined above (table 10)
Table 10: Autonomic Function Results
Insulin Pulse at
baseline
(beats/min)
Onset of 
autonomic 
response 
(min)
Pulse at 
autonomic 
response 
(beats/min)
Pulse at 
blood
glucose 2.4
mmol/1
(beats/min)
Detemir N 14 11 11 9
Mean 63 257 75 65
Median 62 250 73 66
SD 6 129 9 6
Minimum 55 60 64 54
Maximum 78 510 94 76
NPH N 14 10 10 7
Mean 61 273 74 74
Median 61 260 76 74
SD 6 81 5 5
Minimum 50 180 64 67
Maximum 75 420 79 84
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Insulin Concentrations
Maximum concentration of insulin detemir occurred at 279 ±102 min at 3496 ± 1488 pmol/1 
and o f NPH insulin at 180 ± 147 min at 183 ± 144 pmol/1 (Figures 21 and 22). As the length 
of each study was variable between subjects these insulin concentration figures only contain 
a few subjects beyond 420 min. The time range for maximum insulin concentration was 
between 120 and 480 min for insulin detemir and 180 to 420 min for NPH.
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Figure 21: Insulin detemir concentration plotted against time from injection (mean ±  
SEM)
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Figure 22: Insulin detemir plotted as time from the blood glucose nadir (mean ±  SEM)
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Figure 23: NPH insulin concentration plotted against time from injection (mean ±  
SEM)
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Figure 24: NPH insulin plotted as time from the blood glucose nadir (mean ± SEM)
The numbers diminish with time in both insulin studies due to the variability in the time of 
the end point. The data plotted against time from nadir uses values interpolated to 10 min 
intervals from the insulin concentrations measured at hourly time points (figures 22 and 24). 
The table below shows the n value at each time point for insulin concentration.
Table 11: Number in each group at each insulin concentration time point
Time (min) Insulin detemir n= NPH insulin n=
0 14 13
60 14 14
120 13 12
180 14 13
240 12 14
300 8 13
360 7 7
480 2 7
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Counterregulation
Adrenaline
There was an increase in adrenaline concentration with declining blood glucose (Figure 25). 
Adrenaline peaked at blood glucose nadir and then declined towards baseline levels (figure 
26). This was similar with both insulins (Figure 24). No statistical difference was observed 
between Cmax (peak baseline adjusted concentration) (IDet 0.82 ± 0.63 nmol/L vs. 0.89 ± 
0.54 nmol/1 p=O.8lO) or Tmax (time of maximum concentration) (IDet 286 ± 115 min vs. 
NPH 326 ± 102 min p=0.545).
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Figure 25: Adrenaline concentration plotted against time from injection (mean ±  SEM)
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Figure 26: Adrenaline plotted as time from blood glucose nadir (mean ±  SEM)
Noradrenaline
Noradrenaline was similar to the baseline concentration until blood glucose nadir when it 
started to increase (Figure 27 and 28). There was no statistical difference in this response 
between the two insulins as measured by Cmax (IDet 0.83 ± 0.63 nmol/L vs. NPH 0.89 ± 
0.82 nmol/L p=0.686) or Tmax (IDet 286 ±115 min vs. NPH 326 ±102 min p=0.271).
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Figure 27: Noradrenaline plotted against time from injection (mean ± SEM)
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Figure 28: Noradrenaline plotted as time from blood glucose nadir (mean ± SEM) 
Glucagon
There was a steady increase in glucagon from baseline to blood glucose nadir (Figures 29 
and 30). There was no significant difference between the two insulin in either Cmax (IDet 
3.7 ± 5.5 pmol/L vs. NPH 2.1 ± 2.5 pmol/L p=0.469) or Tmax (IDet 156 ± 153 mins vs. 
NPH 206 ± 173 mins p=0.919).
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Figure 29: Glucagon plotted against time from injection (mean ± SEM)
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Figure 30: Glucagon plotted as time from blood glucose nadir (mean ± SEM)
Cortisol
The cortisol response was similar with both insulins and no significant difference was 
demonstrated in either the CMax (IDet 24 ± 49 nmol/1 vs. NPH 15 ± 28 nmol/1 p=0.485) or 
Tmax (IDet 161 ± 165 mins vs. 139 ± 162 p=0.345) (figures 31 and 32)
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Figure 31: Cortisol plotted against time from injection (mean ± SEM)
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Figure 32: Cortisol plotted as time from blood glucose nadir (mean ± SEM)
Growth Hormone
GH increased at the time of blood glucose nadir as would be expected and this was similar 
between insulin detemir and NPH insulin (figures 33 and 34). There was no statistical 
difference in CMax (IDet 47.7 ± 46.1 mll/L vs. 49.5 ± 26.0 mU/L p =0.608) or Tmax (IDet 
225 ± 143mins vs. 290 ± 117mins p=0.692) between insulin detemir and NPH insulin.
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Figure 33: Growth Hormone plotted against time from injection (mean ± SEM)
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Figure 34: Growth Hormone plotted as time from blood glucose nadir (mean ±  SEM) 
IGFBP1
There was a decline in the concentration of IGFBP1 as the blood glucose declined. This 
decrease continued after the blood glucose nadir (Figure 35 and 36). There was no statistical 
difference in CMax (IDet 27.83 ± 26 ng/ml vs. NPH 14.41 ± 14.27 p=0.697) or Tmax (IDet 
66 ± 66 min vs. NPH 73 ± 75 min p=0.692).
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Figure 35: IGFBP1 plotted against time from injection (mean ± SEM)
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Figure 36: IGFBP1 plotted as time from blood glucose nadir ± SEM)
NEFA
There was a small rise in NEFA concentrations as would be expected in hypoglycaemia but 
this was not significantly different from the baseline value. There was no difference in 
NEFA concentrations between the two insulin preparations (Figure 37 and 38).
1 -  
0.9 - 
0.8  -
I  -
E 0.6 - 
i .  0.5 - 
<  0 .4 -
g  0.3 - 
0.2 -
0.1 -
-100 0 100 200 300 400 500
Time (min)
Figure 37: NEFA plotted against time from injection (mean ± SEM)
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Figure 38: NEFA plotted as time from blood glucose nadir (mean ± SEM)
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CHAPTER 4
DISCUSSION
In clinical trials it has been widely reported that there is less overnight hypoglycaemia when 
insulin detemir is compared to NPH insulin when used as part of a treatment regimen 
(Pieber et al 2000, Ratner et al 2000, Vague et al 2003, Hermansen et a 2004, Home et al 
2004, Russell-Jones et al 2004, Kolendorf et al 2006). This study set out to compare equal 
doses of s.c. insulin detemir and NPH insulin given under controlled conditions to examine 
if there was a difference between the insulins in hypoglycaemia symptoms, autonomic 
response, cognitive function, glucose profiles, EGP and PGU and counterregulatory 
hormone response.
This study showed that during hypoglycaemia in type 1 diabetes insulin detemir had a 
greater effect than NPH insulin on the suppression of EGP and a lesser effect than NPH 
insulin on the stimulation of PGU. Awareness of hypoglycaemia (as measured by the 
Edinburgh Hypoglycaemia Score), crucial to individuals with type 1 diabetes which allows 
them to manage their control safely and effectively was not demonstrated to be different. In 
addition the counter-regulatory hormone response was not demonstrated to be significantly 
different between the two insulins.
This study represents a fairly typical cross section of the population in Surrey with type 1 
diabetes recruited from the Royal Surrey County Hospital Diabetes Database. The original 
number of participants studied in total was 22 which include the sub group dosed at 0.4 
U/Kg. Eighteen were studied at the 0.5 U/Kg dose but paired data was obtained on 14 which
is why the final analysis was done using this group. From the power calculation 18 
participants would be sufficient to detect a difference in hypoglycaemia symptoms o f 10 at a 
power o f 81% whereas 14 subjects gave a power of 69% to detect this difference (table 4 
p83). It is possible that a larger number of participants would have demonstrated a 
difference in the hypoglycaemia awareness end points or counterregulatory hormone 
response but there are other factors such as the level o f hypoglycaemia achieved which are 
likely to be more important.
The glucose profiles were similar with each insulin and no difference was observed in the 
shape of the blood glucose profile or glucose end point. Inter and intra-individual variation 
was observed when looked at in isolation but this did not achieve significance in the final 
analysis. Because of the design o f the study, administering insulin subcutaneously rather 
than as a hyperinsulinaemic hypoglycaemic clamp, a greater than anticipated variation in 
responses to subcutaneous injection was seen in the blood glucose profiles between subjects 
and between study visits. This was why the blinded results of the blood glucose profiles 
were reviewed after the first five subjects had been dosed at 0.4 U/Kg. The dose increase 
was initiated because the first five subjects for which there was paired data did not show a 
consistent response or achieve the desired end point. This continued to be the case with 
those dosed at 0.5 U/Kg but the decision was taken not to increase the dose in case this 
moved further away from a clinically relevant dose. Many participants reached a plateau at a 
higher blood glucose than the target o f 2.4 mmol/l (in some cases this plateau lasted over 60 
min) and although encouraged to continue were uncomfortable and the study had to be 
terminated.
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The mean (± SEM) end points of 2.6 ± 0.5 mmol/l following insulin detemir and 2.8 ± 0.6 
mmol/l following NPH insulin at blood glucose nadir were higher than target. Larger 
numbers of participants would probably have increased the number of observations nearer to 
the target glucose concentration.
The methodology used in this study was intended to mimic clinical practice but was not 
designed to look specifically at an individual’s glucose threshold as would be the case with 
intravenous hypoglycaemic clamp methodology. The forearm vein used for sampling was 
heated. In glucose clamp methodology when studying hypoglycaemia retrograde 
cannulation and a heat box are used to obtain arterialised blood samples, which is important 
when determining hypoglycaemic thresholds. This arterialised sample is accepted as a more 
accurate reflection of the glucose concentration delivered to brain tissue (Liu et al 1992) but 
hand heating does not necessarily show a difference in the results for glucose concentration 
compared to plasma samples and can be uncomfortable (Green et al 1992).
The original study design had been to base the study end point on plasma glucose 
concentrations rather than blood glucose concentrations. Using plasma glucose 
concentrations would have meant initial blood glucose analysis (done first for safety in 
hypoglycaemia) would have taken 1 min using the YSI glucose analyser if  it worked on the 
first occasion, centrifuging and separating the samples afterwards, which took 10 min and 
then after separating a re-analysis of plasma glucose concentration taking a further min. 
Alternatively plasma glucose could have been used without a guide blood glucose sample
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which would have meant an approximate delay o f 11 minutes after drawing the sample 
before the results could be acted upon Although originally blood glucose concentration 
instead o f plasma glucose was used to determine the study end point by mistake for the first 
few subjects, when this was realised early on in the study it was decided to continue with the 
measurement o f blood glucose both on the basis of safety (due to the falling glucose 
concentration) and also the variability in end point glucose. It was felt this was unlikely to 
make a difference to the end result.
Glucose metabolism
This study suggests that insulin detemir has a greater effect than NPH insulin on the 
suppression of endogenous glucose production and a lesser effect than NPH insulin on the 
stimulation of PGU when glucose concentration was at or below 3.5mmol/l. Under normal 
physiological post-absorptive conditions euglycaemia is maintained by portal insulin acting 
to modulate hepatic glucose production (Sindelar et al 1998). In type 1 diabetes severe 
insulin deficiency reveals much more o f the hepatic insulin dose-response curve. Fasting 
hyperglycaemia is due to increased production o f glucose from the liver both by 
unrestrained glycogenolysis and increased gluconeogenesis (Boden et al 2003).
For this reason in type 1 diabetes when there is severe hyperglycaemia, glucose flux is 
increased rather than less than normal (Luzi et al 1988, Hall et al 1979). In the absence of 
adequate direct insulin action in the liver the excess glucose production is so great that even
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an increase in glucose dependent PGU and the associated glycosuria fail to limit progressive 
hyperglycaemia.
The hypothesis was that at any given value o f hypoglycaemia glucose flux would be greater 
with NPH insulin than with insulin detemir. The results support this hypothesis. At baseline 
after human soluble insulin infusion there were no differences in EGP and PGU between 
studies. After dosing with either insulin detemir or NPH differences appeared with detemir 
having a greater effect than NPH insulin at suppressing EGP and less effect at stimulating 
PGU. With NPH insulin equivalent levels of hypoglycaemia were partly dependent on a 
relatively greater stimulation of glucose disposal. This could be consistent with a 
hepatoselective effect o f insulin detemir compared to NPH insulin.
A previous study had also shown that insulin detemir had a greater effect on EGP than NPH 
at normoglycaemia in glucose clamp experiments in subjects without diabetes (Hordern
2005). In subjects without diabetes the effects of s.c. insulin detemir at low dose (9nmol/Kg) 
and high dose (1.8 nmol/Kg) and NPH insulin at an equivalent to the high dose (1.8 
nmol/Kg) were compared during a euglycaemic clamp. There was no difference in the 
glucose profile (glucose infusion rate) between insulin detemir and NPH but insulin detemir 
had a greater effect on the suppression of EGP (pO.Ol) however suppression o f NEFA 
appeared to be less with insulin detemir compared to NPH. In subjects with type 1 diabetes a 
study comparing the insulin analogues insulin glargine and insulin detemir using clamp 
methodology at normoglycaemia, suppression of lipolysis measured by NEFA and glycerol 
concentration has also appeared to be less with insulin detemir when compared to insulin
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glargine (Porcellati et al 2007). This may reflect a lesser peripheral action of insulin detemir 
at the adipocytes.
Clamp studies may not be the best experimental method to investigate hepatic glucose 
production. The euglycaemic hyperinsulinaemic clamp is the usual method for investigating 
the action of insulin preparations on glucose metabolism. In most such experiments 
euglycaemia is the starting condition then modified by addition of further insulin 
stimulation. It follows that the starting condition in these experiments falls very near the top 
of the dose-response curve for insulin action in the liver and near the bottom of the dose 
response curve for glucose uptake in peripheral tissues. The prevention of hypoglycaemia by 
clamping serves further to focus attention on peripheral insulin action as any fall in glucose 
dependent glucose uptake due to developing hypoglycaemia is eliminated by the glucose 
infusion. Glucose clamp experiments can underestimate the vital physiological significance 
of hepatic insulin action and in the most extreme cases doubt has even been expressed that 
insulin has any major direct action in the liver even when glucagon levels are raised 
(Mittelman et al 1997)
Factors that could influence hepatic exposure to subcutaneously delivered insulin include 
rate of absorption from the injection site into the venous system, the volume of distribution, 
possible insulin extraction in the pulmonary and mesenteric capillary beds before reaching 
the hepatic artery and the blood flow in the hepatic artery. The concentration of insulin after 
intraportal administration is affected only by portal vein flow (from the gut). Physiological 
portal insulin delivery may have metabolic advantages over peripheral insulin delivery and 
animal studies have suggested this to be the case. In partially pancreatectomised dogs
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peripheral and portal glucose tolerance tests and hyperglycaemic clamp studies have 
indicated that intraportal hyperglycaemia and hyperinsulinaemia promote hepatic glucose 
handling (Kubota et al 1996). Investigation of peripheral versus portal insulin delivery on 
hepatic glucose production in dogs using radioactive isotopes of glucose have shown that 
both methods of delivery exerted an equally potent effect on reduction o f net hepatic glucose 
output but that the portal route had a far more rapid onset of effect (Sindelar et al 1996).
In humans without diabetes when portal insulin was elevated with tolbutamide versus 
peripheral infusion (matched to the portal concentration by calculation) EGP was suppressed 
to a greater extent with portal versus peripheral insulin delivery (Lewis et al 1996). In 
contrast to the above, other studies have suggested that peripheral insulin delivery has a 
greater effect on EGP than portal insulin delivery. Glucose clamps in moderately 
hyperglycaemic de-pancreatectomised dogs showed that peripheral insulin infusion inhibited 
EGP to a greater extent when compared to an equivalent dose of portal insulin. Portal and 
half dose peripheral infusions resulted in matched peripheral insulinaemia and similar 
suppression of glucagon and inhibited glucose production equally (Giacca et al 1992).
Other work by the same author showed suppression of glucose production was proportional 
to the hepatic insulin levels and systemic insulin levels did not dominate suppression of 
glucose production in modest hyperglycaemia (Giacca et al 1997). A follow up study carried 
out at euglycaemia (~6 mmol/l) instead of hyperglycaemia (-10 mmol/l) showed that there 
was greater suppression of EGP with portal insulin and the previous study findings were 
hypothesised to be due to the hyperglycaemia and or the diabetic state (Gupta et al 2002).
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An alternative explanation for the difference between NPH and insulin detemir observed in 
clinical studies has been hypothesised; that the reduced incidence of hypoglycaemia with 
insulin detemir is due to a higher concentration of insulin detemir in the cerebrospinal fluid 
affecting brain responses to hypoglycaemia (Rossetti et al 2008). Albumin may penetrate the 
cerebrospinal fluid through the choroid plexus (Knott et al 1997) and the more lipophilic a 
molecule is the higher its concentration may be in cerebrospinal fluid (Shen et al 2004). 
Insulin detemir may exist at higher concentration in the CSF due to its lipophilic nature 
(Rossetti et al 2008).
Subjects without diabetes were studied with i.v. insulin detemir or human insulin at 
euglycaemia or step wise hypoglycaemia with the aim to explore whether a difference in the 
brain/hypothalamus response could be demonstrated using equipotent doses o f human 
insulin and insulin detemir (Rossetti et al 2008). As in the current study plasma 
counterregulatory hormone response to hypoglycaemia did not differ between insulin 
detemir and human insulin (actrapid). Compared to human insulin however, a higher 
glycaemic threshold (i.e. responses occurred at a lower glucose concentration) for adrenergic 
symptoms and also a higher maximal response for adrenergic symptoms and 
neuroglycopenic symptoms scores occurred with insulin detemir. The onset of cognitive 
dysfunction occurred at a higher glucose concentration with insulin detemir compared to 
human insulin. These results are at odds with the hypothesis o f this study, showing exactly 
the reverse in terms of hypoglycaemia recognition and cognitive ability in hypoglycaemia.
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The findings of an increased maximal adrenergic symptom response were more in keeping 
with this study hypothesis and similar to the increased sweating symptoms observed in a 
similar previous study (Tschritter et al 2009).
The observation of a difference between the two insulins in hypoglycaemia could be 
explained by the difference in methodology from the current study and Rossetti et al which 
looked specifically at glycaemic thresholds using intravenous insulin and stepwise 
hypoglycaemic clamps in subjects without diabetes. This may influence brain sensing of 
hypoglycaemia as higher insulin concentrations in the cerebrospinal fluid may cause greater 
counterregulatory responses, increase symptoms and deterioration of cognitive function to 
insulin induced hypoglycaemia (Rossetti et al 2008, Galâsetti and Davis 2000).
In the study described here the aim was to reproduce clinically relevant circumstances 
allowing the exploration of the events that occur when in type 1 diabetes an inappropriate 
excess o f subcutaneous insulin results in a drift into hypoglycaemia.
Hypoglycaemia Symptom Score, autonomic function and cognitive function
This study did not show an appreciable difference in the hypoglycaemia symptom score, 
autonomic function or cognitive function between the two insulins. There was not a 
particularly marked deterioration in any of these parameters from baseline, possibly due to 
not enough subjects reaching the blood glucose target nadir.
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Although subjects were screened for diminished hypoglycaemia awareness verbally and on 
the basis o f their case notes, as an observer there was a difference in the level of 
hypoglycaemia that was tolerated by different individuals, some being noticeably lower than 
others. This effect on symptoms has been observed in intensively treated patients compared 
to those with conventionally treated type 1 diabetes and those without diabetes, the latter 
two groups showing symptoms at a higher glucose level (Maran et al 1995). As this was a 
cross over study this would not influence the ability to detect a difference between the 
insulin preparations but may have had an effect on the overall ability to detect a change in 
symptoms and autonomic function compared to baseline.
The other studies discussed previously (Rossetti et al 2008, Tshritter et al 2009) that have 
reported a difference in symptomatic response to hypoglycaemia are in subjects without 
diabetes. In one study the symptom of sweating was greater with insulin detemir at blood 
glucose levels o f 3.0 and 2.3 mmol/l; otherwise there was no observed difference in other 
symptoms of hypoglycaemia or counterregulatory hormone response (Tschritter et al 2009). 
A hyperinsulinaemic euglycaemic ramp with both i.v. insulin detemir and human insulin in a 
cross-over trial showed a difference in the magnitude o f adrenergic symptoms and 
neuroglycopenic symptoms (p<0.05) (Rossetti et al 2008). The glycaemic threshold for 
onset o f symptoms with insulin detemir occurred at a plasma glucose o f 51 ± 7.7 mg/dl (2.8 
± 0.4 mmol/l) whereas with human insulin it was 56 ± 7.8 mg/dl (3.08 ± 0.43 mmol/l) 
(p=0.029) It is difficult to directly compare these studies where insulin detemir was 
compared to human insulin given intravenously to subjects without diabetes, although the 
plasma glucose concentration (Rossetti et al 2008) and the blood glucose concentration
121
(Tscritter et al 2009) in hypoglycaemia was similar to the blood glucose concentration at 
nadir in this study.
Both previous studies point out that the reasons for the differences observed in the responses 
to hypoglycaemia are not known. The Rossetti study hypothesises that this is due to insulin 
detemir and human insulin exerting differential actions on the brain where responses to 
hypoglycaemia are generated and that higher cerebral concentrations o f insulin may evoke 
greater counterregulatory hormone response, greater symptom response and a greater 
deterioration of cognitive functions (Rossetti et al 2008).
The cognitive function tests used in this study were not sensitive enough to detect a change 
at the nadir blood glucose concentration when compared to baseline. The four choice 
reaction time would be expected to deteriorate between plasma glucose concentrations of 2.8 
to 3.0 mmol/l in individuals with and without diabetes (3.0 mmol/l when using whole blood) 
(Boyle 1994, Maran 1995) and this was equivalent to the mean end point glucose 
concentration in this study. The other less sensitive finger tapping test deteriorates at a 
plasma glucose of 2.3 mmol/l (Hopkins 1998).
Cognitive function in the study by Rossetti et al (2008) discussed above was shown to be 
different with the threshold for the onset of cognitive dysfunction earlier with insulin 
detemir versus human insulin at a plasma glucose o f 51 ± 8.1 vs. 47 ± 3.6 mg/dl (2.8 ± 0.45 
mmol/l vs. 2.6 ± 0.2 mmol/l). The cognitive function tests used were more extensive than 
the current study and more sensitive at higher glucose thresholds. They included trail
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making tests, stroop, verbal memory test, backwards digit span and paced auditorial serial 
addition. The study therefore examined a wider scope o f cognitive function than in the 
present study and thus would be more likely to detect a difference if one existed.
Insulin, counterregulatory hormones, IGFBP1 and NEFA
The pharmacokinetic data on insulin concentration has diminishing numbers from 360 min 
onwards due to the variable end point time in each study. The time action profile of insulin 
detemir (Tmax) has been shown in clamps to be 446 ± 162 min and NPH 360 ± 175 min 
(Heineman et al 1999). The insulin concentrations in this study are within this time action 
profile and also showed that, time to maximum insulin concentration of insulin detemir took 
longer than with NPH insulin.
The counterregulatory responses were not demonstrated to be different in this study. Most of 
the counterregulatory hormones showed the expected response to hypoglycaemia. It may be 
that the number o f subjects in this study, being smaller than originally planned due to failure 
to achieve hypoglycaemia on both occasions, meant that the study was under powered to 
detect a difference. This is a similar finding to the 2 other studies comparing insulin detemir 
to human insulin in participants without diabetes discussed above (Tschritter et al 2009, 
Rossetti et al 2008). This study did not examine a clear threshold o f counterregulatory 
response to hypoglycaemia as would be examined in a hypoglycaemic clamp due to the 
nature o f the study design.
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Adrenaline response showed at clear peak at blood glucose nadir before declining towards 
baseline, noradrenaline stayed similar to baseline until blood glucose nadir when it started to 
rise. This is consistent with counterregulation of hypoglycaemia demonstrating that this 
occurred at the level of hypoglycaemia achieved in this study (2.6 ± 0.5 mmol/1 with insulin 
detemir, 2.8 ± 0.6 mmol/1 with NPH insulin). In individuals with type 1 diabetes this 
response would be expected at a plasma glucose concentration o f up to 1 mmol lower than 
in subjects without diabetes where adrenaline and noradrenaline release occurs around 3.6- 
3.9 mmol/1 (Amiel 1988, Cryer et al 2003).
The duration of type 1 diabetes was 13 ± 9.8 years in the present study, glucagon responses 
have been shown to be diminished in subjects with type 1 diabetes when compared to those 
without diabetes (Bolli et al 1983, Liu et al 1993, Sjoberg et al 2002). Glucagon responses in 
hypoglycaemia have been shown to be inversely proportional to the duration o f diabetes 
(Bolli et al 1983). There was a glucagon response to hypoglycaemia in this study but it was 
not marked which might be expected in this study group due to the duration of diabetes in 
some subjects although there was not a clear correlation o f duration of diabetes and 
glucagon response on examination o f the raw data.
The cortisol rise compared to baseline was not particularly marked. This study commenced 
in the morning around 6am when cortisol levels are high due to diurnal variation and there 
was also a degree o f stress involved in taking part in the study which may have blunted the 
observed response.
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The GH response to hypoglycaemia peaked at blood glucose nadir showing that 
counterregulation occurred. GH did increase more with hypoglycaemia induced by insulin 
detemir but this did not reach statistical significance however this trend was also observed in 
one other study but it did not achieve statistical significance (Rossetti et al 2008). GH and 
cortisol are less important in immediate counterregulation o f hypoglycaemia when 
compared to that o f adrenaline response and glucagon response as the first line of defence.
The IGFBP1 level fell gradually both with time and declining blood glucose concentration 
with both NPH insulin and insulin detemir. This finding is consistent with a study which did 
not show a difference in the decline of IGFBP1 when i.v. insulin detemir was compared to
i.v. human insulin using a stepwise hypoglycaemic clamp in participants without diabetes 
(Porcellati et al 2009). A rise in IGFBP1 would be expected with hypoglycaemia in subjects 
without diabetes and has been suggested to be a result o f the suppression of endogenous 
insulin (Cotterill et al 1993). In subjects with type 1 diabetes IGFBP1 levels have been 
shown to fall with exogenous insulin given as a bolus intravenously compared to a rise in 
IGFBP1 in control subjects (Quin et al 1994).
The expected response to hypoglycaemia would be a rise in NEFA compared to baseline 
reflecting an increase in lipolysis with declining glucose concentration. NEFA have been 
demonstrated to exert a more profound counterregulatory effect to hypoglycaemia on 
hepatic glucose production than on glucose utilization in subjects without diabetes (Fanelli 
1993). The NEFA response is a balance between the amount of insulin which will oppose 
any effects of the counterregulatory hormones in hypoglycaemia where insulin levels are
125
low in non diabetes. In a hypoglycaemic clamp study comparing insulin detemir and human 
insulin NEFA were shown to be less suppressed with insulin detemir when compared to 
human insulin in subjects without diabetes (Rossetti et al 2008). This finding suggests that in 
this context in subjects without diabetes the reduced suppression of lipolysis may contribute 
to counterregulation at the liver by increasing EGP (Fanelli 1993) however a difference in 
NEFA response was not shown in the current study to explain the higher levels of EGP and 
lower PGU with insulin detemir when compared to NPH insulin.
CONCLUSION
Insulin detemir and NPH insulin induced similar glucose lowering effects when 
administered subcutaneously to subjects with type 1 diabetes. At baseline before the 
injection o f insulin there was no observed difference between EGP and PGU. EGP was 
consistently lower with insulin detemir when compared to NPH at glucose concentrations o f 
3.5 mmol/1 and lower suggesting that insulin detemir exerted a greater suppressive effect on 
EGP (p=0.001). Similarly PGU was observed to be consistently lower with insulin detemir 
when compared to NPH insulin at the same glucose concentration suggesting that insulin 
detemir exerts a lesser effect on PGU (p=0.005). Results presented here are consistent with a 
relatively hepatoselective effect o f insulin detemir adding weight to the suggestion that the 
capillary endothelial barrier in peripheral tissue limits the transfer of detemir insulin from 
the circulation into the extravascular space. Further potential clinical advantages of this 
phenomenon deserve exploration.
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Although not tested by the study described here it is possible that counter-regulatory 
mechanisms would more adequately correct hypoglycaemia occurring with less 
inappropriate insulin stimulation o f peripheral glucose uptake. The counter-regulatory 
hormone response to insulin acts predominantly on stimulating EGP. The differential and 
more physiological effect o f insulin detemir suggested by this study could explain the 
reduced episodes of hypoglycaemia observed in clinical studies when detemir is compared 
to NPH (Vague et al 2003, Russell-Jones et al 2004, Hermansen et al 2001, Kolendorf et al
2006). Alternatively it is possible that differences in the effects of detemir and human 
insulin in the brain (Rossetti et al 2008) could exert influence in these respects perhaps due 
to a higher concentration in cerebrospinal fluid.
Future studies
To explore the difference shown in EGP and PGU insulin and to further evaluate symptom 
response and counterregulation of hypoglycaemia when insulin detemir is compared to NPH 
similar methodology could be employed but with a larger dose of insulin to attempt to try to 
achieve more consistent and a lower level of hypoglycaemia (e.g. 0.6 units/Kg, higher doses 
would not compare to clinical practice). An alternative would be to use hypoglycaemic 
clamp methodology although this would not be representative of the use o f basal insulin 
preparations in clinical practice. It would be ideal to study greater numbers of participants to 
increase the chances of detection of a difference in symptom response to hypoglycaemia if 
one exists. A more extensive battery of cognitive function tests would examine different 
aspects of cognitive deterioration but also to choose tests which are a more sensitive
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measure of cognitive deterioration in lesser degrees o f hypoglycaemia. It would also be 
interesting to compare the response to hypoglycaemia when insulin detemir is compared 
with NPH and also with insulin glargine.
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APPENDIX 1: Hypoglycaemia Symptoms Score 
DO YOU FEEL HYPO?
YES NO
Please circle the most appropriate response
Symptom Not very much "► A great deal
Sweating
Palpitations
Shaking
Hunger
Confusion
Drowsiness
Odd behaviour
Speech difficulty
Incoordination
Headache
Nausea
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APPENDIX 2: Presentations
Poster presentation published as an abstract. American Diabetes Association, 67th 
Scientific Session. Chicago 2007.
F Smeeton1, F Shoajee-Moradie2, N Jackson2, L Westergaard,3,Endahl L3, Haahr H3, A M 
Umplebey2, D Russell-Jones1.
1The Royal Surrey County Hospital, Guildford.
2 The Postgraduate Medical School, University of Surrey, Guildford.
3N ovo  Nordisk A/S
No Difference in Cognitive Function, Symptoms or Counter-Regulatory Responses 
after Induced Hypoglycaemia in Subjects with Type 1 Diabetes.
Insulin detemir is a basal insulin with the unique property o f being bound to albumin. 
Previous studies have shown reduced frequency of hypoglycaemia and less weight gain 
when used in treatment of Type 1 diabetes compared to NPH insulin. To compare the effects 
of detemir and NPH during hypoglycaemia 23 patients with Type 1 diabetes were enrolled 
in a double blind, randomised, cross over trial. Following an overnight insulin sliding scale 
either NPH or detemir was injected subcutaneously and blood glucose was allowed to fall to 
a minimum of 2.4 mmol/1.
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Figure shows mean blood glucose ± SEM to blood glucose nadir
Symptoms of hypoglycaemia, cognitive function, autonomic response in heart rate and 
blood pressure were recorded at regular intervals. Blood was taken for insulin, glucagon, 
adrenaline, noradrenaline, growth hormone, cortisol, NEFA and IGFBP1.
The first five subjects were dosed at 0.4 U/kg and the subsequent 18 at 0.5 U/Kg. The 
expected physiological responses to hypoglycaemia were observed. No difference in the 
blood glucose profiles, symptoms, cognition, autonomic response or counter-regulatory 
hormone response were demonstrated with insulin detemir and NPH insulin. These results 
are reassuring and important as thousands of patients are now being treated with insulin 
detemir worldwide.
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Oral presentation published as an abstract. European Association for the Study of  
Diabetes 43rd Annual Meeting. Amsterdam, 2007
F Smeeton1, F Shoaj ee-Moradie2, N Jackson2, R H Jones2, A M Umpleby2, D Russell- 
Jones1.
departm ent o f Diabetes and Endocrinology, The Royal Surrey County Hospital.
2The Wolfson Centre for Translational Research, The University of Surrey, Guildford,
United Kingdom.
Is Insulin Detemir Hepatoselective When Compared to NPH Insulin Using Stable 
Isotope Methodology at Plasma Glucose Concentrations o f Less Than 4 mmol/1?
Insulin Detemir has shown a greater effect on suppression of endogenous glucose 
production compared to NPH insulin in euglycaemic clamp studies in individuals without 
diabetes. There is also a lower incidence of hypoglycaemia when compared to NPH insulin 
in clinical studies when used to treat diabetes. Insulin detemir is a basal insulin with the 
unique property of being bound to albumin. This may explain some of its observed effects 
by a more physiological action, with greater suppression of endogenous glucose production 
and lesser effect on peripheral glucose uptake.
Fourteen participants with type 1 diabetes were studied in a double blind cross over trial 
after subcutaneous injection o f insulin detemir compared to NPH insulin when fasted. A 
continuous infusion of [6, b-2H^j glucose enabled endogenous glucose production and 
peripheral glucose uptake to be calculated.
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Figure: Endogenous glucose production at time zero before injection o f subcutaneous 
injection of either insulin detemir or NPH insulin and at decreasing plasma glucose 
levels.
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No significant difference was observed between starting plasma glucose or endogenous 
glucose production before administration of insulin detemir or NPH insulin (plotted 
separately on the figure). Insulin detemir had a greater effect on suppression o f endogenous 
glucose production when compared to NPH insulin at plasma glucose concentrations below 
4 mmol/l. This provides further evidence that insulin detemir is hepatoselective.
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APPENDIX 3: Publication
F Smeeton, F Shojaee-Moradie, N Jackson, R H Jones, A M Umpleby, D Russell-Jones. 
Differential effects o f insulin detemir and neutral protamine hagedorn (NPH) insulin 
on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in 
type 1 diabetes. Diabetologia 2009 52: 2317-23.
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